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General Introduction
Cholera Disease
Vibrio cholerae is a gram-negative, curved rod-shaped bacterium that causes the severe
diarrheal illness cholera. When a host ingests large quantities of fecal-contaminated water or
raw shellfish colonized with V. cholerae, disease can occur within a short incubation period
from as little as two hours to up to five days. Cholera is characterized by severe dehydration
and shock caused by voluminous watery diarrhea, colloquially known as “rice-water stool” as its
appearance is similar to water left over from washing rice. Other symptoms include vomiting,
leg cramps, and decreased skin turgor due to the dehydration (1, 2). Treatment includes oral
rehydration solution (ORS) as specified by the World Health Organization (WHO) to contain
strict amounts of various salts including sodium chloride, trisodium citrate dihydrate, and
potassium chloride, as well as glucose (3). For severe patients, additional IV fluids containing
sodium and glucose are administered to relieve dehydration. As cholera patients can lose up to
one liter of water per hour in the early stages of the disease, ORS not only hydrates the patient,
but also insures that cholera patients have their sodium levels replenished in the small intestine
(4, 5). In addition, antibiotics also may be used conjointly to slightly shorten the disease
symptom duration and reduce the period of time that there is bacterial shedding into the
environment.
Approximately 75% of people show no symptoms when infected with V. cholerae;
however, these carriers can still shed bacteria for 7-14 days, albeit at lower amounts than a
person showing symptoms. In addition, carriers can still infect other people (6, 7). For the
children or adults who develop symptoms, approximately 80% experience mild or moderate
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symptoms, with the remaining 20% experiencing severe symptoms that include massive
dehydration and diarrhea. Without treatment, survival is approximately 50% and death can
occur within a few hours after the onset of diarrhea; however, with treatment survival is
approximately 99% (8).

Global Impact of Cholera
Although scholars disagree on when the first instances of cholera occurred, there is
historical evidence of a disease that resembles cholera dating back thousands of years in the
Indian subcontinent. The origins of the word cholera likely come from the Greek words “chole,”
meaning bile, and “rein,” meaning to flow, first used in Hippocrates writing around 400 BC.
Written accounts of cholera also appear in Sanskrit around 500 BC (9). The first recorded
pandemic of cholera occurred in 1817, as traders visited India and carried the disease with
them, and since then a total of seven pandemics have occurred, with the most recent, seventh
pandemic still ongoing (10). As the world became more industrialized, cholera likely spread
following trade and immigration routes, and first reached the United States in 1832 (11). It was
initially thought cholera spread through inhalation of a foul-smelling pollution known as
miasma, but this myth was dispelled during the third pandemic that occurred in the 1850s (9).
John Snow, a practicing physician in London, showed in 1854 that the source of a large and very
deadly outbreak of cholera was a town water pump in the Soho region of London (12). Once
the pump was decommissioned, the epidemic ended in this region of London (12). Around this
same time, Filippo Pacini isolated “comma-like” shaped bacteria from the intestinal lumens of
deceased cholera patients and described these as both infectious and the causative agent of
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the disease (13). However, his publication was written in Italian and was not widely
disseminated. It was not until 1884, one year after Pacini’s death, that Robert Koch
rediscovered V. cholerae from patients and publicized the information, therefore getting credit
for many years as the initial discoverer of V. cholerae (13).
In regards to recent cases of cholera, the WHO reported that the incidence of cholera
had increased steadily from 2005-2012, and although the number of reported cases has
decreased since then, it continues to be a concern (14). This is especially true in the developing
world, where access to clean water and adequate sanitation is a problem. In 2013, 129,064
cases of cholera were officially reported to WHO, resulting in 2,102 deaths, but the number of
cholera cases each year is actually estimated to be between 1.4-4.3 million cases with 28,000142,000 deaths worldwide (14, 15).

This large discrepancy between reported cases and

estimated cases may in part be due to underreporting because of lack of consistency in case
definitions, but also because of the negative political and economic implications on travel and
trade resulting from a publicized cholera epidemic.
Cholera is currently endemic in approximately 50 countries, mainly within Asia and
Africa. From the mid-1990s until 2010, the continent of Africa reported the greatest number of
cases, but in 2010 an earthquake hit Haiti, resulting in a massive increase in cholera cases in the
Americas (14). As a result of the earthquake, there was infrastructure breakdown and, within a
month, a cholera outbreak occurred, spreading throughout the entire country and eventually to
the Dominican Republic and Cuba. This ongoing outbreak has led to over 700,000 cases and
over 8,000 deaths (2).
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V. cholerae is classified based on the O antigen of its lipopolysaccharide, and despite the
fact there are over 200 serogroups in the environment, all seven pandemics have been
attributed to one serogroup, O1 (1, 8, 16). The O1 serogroup can be further divided into two
biotypes: classical and El Tor. Historically, the classification difference has been based upon
different phenotypes such as hemolysis, hemagglutination, phage lysis and polymyxin B
resistance, but more recently, it has been shown that the two biotypes are genotypically
different as well (17, 18). The classical biotype was the causative agent of the first six
pandemics, while the El Tor biotype has caused the most current pandemic (8, 16). The classical
biotype also causes a more severe disease, but El Tor is thought to survive better in the
environment, although the reasons for this are not understood (16, 17). One additional
serogroup, O139, emerged in 1992 and is the causative agent of more recent outbreaks (18-21).
O139 is genetically very similar to O1 EL Tor biotype, suggesting horizontal gene transfer of the
O antigen biosynthetic genes, which in turn, caused the conversion (18, 22, 23). As such, some
refer to these outbreaks as an eighth pandemic (18).
Even though cholera is a huge problem worldwide and much work has been done to
make effective vaccines, there are no current vaccines that offer long-term or complete
protection. Two oral cholera vaccines are available: the first is called Dukoral and is composed
of killed whole cells in a mixture of the two biotypes of O1 V. cholerae, plus a recombinant B
subunit of the cholera toxin (to be discussed later), and another called Shanchol that has both
O1 and O139 serogroups. Dukoral is manufactured by SBL Vaccines in Sweden and prequalified
and licensed in over 60 countries, but not the United States (24). Shanchol is manufactured by
Shantha Biotec in India and in 2011 acquired WHO prequalification and was used in a 2012 pilot
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study to look at feasibility, not efficacy, of mass vaccination in Haiti (25-27). Disappointingly,
both of these vaccines need to be taken in multiple doses and have been shown only to be
about 50-60% effective in the first year (28, 29). Injectable vaccines of whole cells are no longer
used. Making an effective vaccine is currently a top priority as stated in the WHO Model List of
Essential Medicines (30). The Centers for Disease Control and Prevention (CDC) currently does
not recommend receiving a cholera vaccination for travelers, and, as stated, neither vaccine is
available in the United States. This is due to the fact that the vaccines only offer partial
protection for a short period of time.

V. cholerae Life Cycle
V. cholerae is found predominantly in the aquatic environment as normal inhabitants of
freshwater, coastal and brackish waters as either free-swimming bacteria or in association with
marine organisms including shellfish, copepods, chironomid egg masses, and vertebrate fish
(31-37).

Changes in weather that affect surface water temperature and therefore

phytoplankton blooms have been correlated with cholera outbreaks (38, 39). In nature, humans
are generally the only host of V. cholerae to get cholera disease, but a very high infectious dose
of around 106-1011 bacteria is necessary to infect healthy individuals (17). In the environment,
both motility and chemotaxis genes are expressed, which are also important at early time
points after human ingestion. Expression of these genes allows the bacteria to pass through the
host’s defenses such as the low pH of the stomach, bile from the duodenum, and the innate
immune system (40, 41). Using its single polar flagellum, V. cholerae is able to traverse the
stomach and enter the small intestine, where it is then able to pass into the protective mucus
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layer of the intestine and colonize the surface of the epithelium in the intestinal crypts and villi
surfaces (42-44). At this point, the bacteria downregulate motility genes and become immotile,
while genes involved in virulence are upregulated (40, 41).

Colonization occurs for

approximately 12-72 hours before symptoms occur (6). Once a person begins to shed the
bacteria through either vomit or diarrhea, termed the “mucosal escape response”, V. cholerae
is in a hyperinfectious state where the infectious dose can be as low as 10-100 bacteria needed
to infect a new host (45-48). Gene expression is now reversed, such that there is
downregulation of genes involved in virulence and upregulation of genes required for motility,
as well as upregulated protease expression that allows detachment from the epithelium (49).
The hyperinfectious state lasts for at least five hours, and seems to be an effective way that the
bacteria can pass from person-to-person, particularly in heavily crowded areas such as a
household, potentially causing an epidemic due to the rapid rate of infection (46, 47). Bacteria
shed from humans have been shown to be in two forms: a more infectious biofilm-like form
with small aggregates of bacteria and a planktonic form (47, 48, 50).
When not in a human host, V. cholerae naturally lives in an aquatic environment. In
aquatic environments, the bacteria live as either free-swimming planktonic cells or attached to
various types of surfaces that can be living or non-living (31, 36, 37, 51-53). As part of the freeswimming state, V. cholerae can persist in a condition traditionally known as viable but nonculturable (54). In this state, the bacteria cannot be cultured on standard media but are still
able to perform some metabolic processes such as protein synthesis and maintain membrane
integrity (55). This state is thought to occur when the bacteria are not associated with chitin,
and therefore are nutrient-deprived (55). The term “viable” has been questioned, as it is
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unclear if the bacteria are actually alive in this state as they cannot be cultured, therefore a
more conservative term of “active but non-culturable” (ABNC) has also been used (6). These
bacteria can regain the ability to multiply when put into a human once again, or are grown in
the presence of eukaryotic cells, and can be cultured after such exposures (56, 57).
When not free-swimming or ABNC, V. cholerae can associate with marine organisms in a
biofilm either on the organism, or on chitin (such as the shell of crustaceans) where chitin can
then be used as a carbon and nitrogen source (58-60). In general, a biofilm is a microcommunity of bacteria that is attached to some surface and is composed of a matrix of DNA,
proteins, and polysaccharides that holds the micro-community together. In V. cholerae, biofilm
formation is mediated by the Vibrio polysaccharide (VPS) regulon, which encodes extracellular
polysaccharide and leads to increased resistance to chlorine (61-63).

Bacteria found in

association with a biofilm, as opposed to free-swimming bacteria, display hyperinfectivity and it
has been postulated that this form is the most likely source of human infections (64-66).
Potentially, this could be at least in part because bacteria associated with a biofilm have
decreased acid susceptibility, which in turn allows the bacteria to better survive throughout the
stomach (67).

V. cholerae Pathogenesis Genes
In order to initiate disease, and potentially cause a pandemic, production of two
virulence factors is necessary: cholera toxin (CT) and toxin co-regulated pilus (TCP). These are
acquired from the mobile genetic elements cholera toxin bacteriophage (CTXφ) and the Vibrio
pathogenicity island (VPI), respectively. CTXφ is a filamentous bacteriophage with a 6.9 kb
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single-stranded DNA genome and is found in all pandemic strain environmental isolates, but
rarely found in non-O1/O139 environmental strains (16). CTXφ is separately inserted in each of
the two V. cholerae chromosomes in the classical strain, but is found tandemly arranged on the
larger chromosome of El Tor (68-71). Uptake of this prophage is dependent on TCP as its
receptor to enter V. cholerae cells and to convert nontoxigenic strains into toxigenic ones (72).
As TCP is expressed in the intestine, this lysogenic conversion occurs inside the host (72). In
addition to encoding the genes for CT, CTXφ also carries genes that encode the zona occludens
toxin (Zot) and accessory enterotoxin (Ace); however, the role in pathogenesis of these
additional toxins remains unclear (71, 73-75). VPI is 40 kb long, and, besides containing the
genes required for TCP production, also encodes a number of other accessory virulence factors.
Like the accessory toxins encoded by CTXφ , most of these accessory factors have poorly
defined roles in pathogenesis (76, 77).
CT, the cause of the voluminous diarrhea in cholera, was first discovered to act as an
enterotoxin by S.N. De in 1959, but it was not isolated until 1969 by Finkelstein and LoSpalluto
(77-79). De discovered that cell-free supernatants for the classical biotype could cause fluid
accumulation in rabbit ligated ileal loops in a similar manner to when V. cholerae cultures were
injected in the loops (78). Since that initial discovery, much research has been conducted on CT.
CT is an 84 kDa protein, part of the large family of bipartite A-B toxins consisting of five smaller
subunits, collectively called the B subunit, responsible for binding the toxin to its target and one
larger subunit, the A subunit, responsible for the toxin action (77, 80-82). The 6 subunit
holotoxin is assembled in the periplasm, and then secreted by a type II secretion system (83).
The B subunit pentamer binds to the receptor of cholera toxin, ganglioside GM 1, found
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associated in lipid rafts on the intestinal epithelial cell surfaces (81, 84-86). This bound complex
is endocytosed and then continues through retrograde transport to the endoplasmic reticulum
(ER) (87-89). Once in the ER, the toxin is able to use the ER-associated protein degradation
pathway to release the A1 subunit into the cytosol of the host (90, 91). Inside the host cell, the
A subunit dissociates from the B subunit, and it is then cleaved by host proteases into two
fragments: A1 and A2. The A1 subunit contains the active site, while the disulfide bondattached A2 subunit functions as a tether to the B subunit pentamer (92). The A1 subunit then
ADP-ribosylates the Gsα subunit of adenylate cyclase causing adenylate cyclase to be locked in
its GTP-bound active state (93). This in turn causes an increased concentration of cAMP,
leading to a rapid secretion of chloride ions from crypt cells and therefore decreased sodium
uptake from the surrounding villus cells (94, 95). This electrolyte imbalance causes an osmotic
gradient which in turn causes massive secretion of water from the cells into the intestinal
lumen (96, 97). This fluid accumulation in the small intestine is the source of the profuse
watery diarrhea associated with the disease.
TCP is the other major virulence factor produced by V. cholerae that is essential to cause
cholera disease (76, 98). TCP is a type IV bundle-forming pilus that is expressed under the same
conditions as CT, thus leading to the term “toxin co-regulated” (99-101). The exact role of TCP
in colonization is not yet defined, as it has not been shown to act as an adhesin for cell-bacteria
interactions, but it has been shown to mediate microcolony formation on the surface of
epithelial cells and therefore its required role may be for inter-bacterial interactions (99).
Assembled TCP bundles are between 5-7nm in diameter and are composed of polymers of the
first protein encoded by the tcp operon, TcpA (99). The 12 gene tcp operon is located on the VPI
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(16). In V. cholerae strains in which tcpA have been deleted, the bacteria are no longer able to
colonize the small intestine, as shown in healthy human volunteer studies (98). TCP is also
involved in the secretion of the colonization factor TcpF, but is not clear how this required
factor is used for colonization (102). It is known that tcpJ is involved in the processing of TcpA
during secretion by encoding a leader peptidase (103). Most of the tcp operon is either involved
in or part of the actual pilus.
Other genes important for host colonization that are located on the VPI have also been
identified, including acfABCD, aldA, tagA, and tcpI, but their roles are largely unknown (1, 104110). The acf genes make up the accessory colonization factor (ACF) and are required for
enhanced intestinal colonization in mice, but the functions of the proteins are still largely
unknown (108). AcfB and TcpI share homology with methyl-accepting chemotaxis proteins, and
when mutated together cause decreased colonization in mice (106, 111, 112). Decreased
colonization does not occur when each gene is mutated individually, suggesting redundancy in
the chemotactic properties of these proteins (106, 111, 112). Two small, non-coding RNAs
encoded by tarA and tarB are also located within the VPI (113, 114). TarA regulates ptsG, a
major glucose transporter, while TarB regulates the secreted TcpF before penetration into the
intestinal epithelial layer (113, 114). When mutated, the aldehyde dehydrogenase aldA does
not show a defect in colonization; however it is coordinately regulated along with the tcp
operon (115). TagA is a metal-dependent mucinase that acts to modify mucin proteins by
cleaving them and potentially leading to enhanced binding of V. cholerae to the cell surface
(116). More work is needed to elucidate the complete role of these and other VPI genes in
disease.
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Motility and Chemotaxis
Motility and chemotaxis have been extensively studied in regard to their roles in
pathogenesis. However, their roles in disease are highly debated as different strains, biotypes,
mutations and animal models can show different, and sometimes opposite results (117-124). As
mentioned previously, V. cholerae is a highly motile bacterium that has a single, polar flagellum.
The flagellum is driven by sodium motive force. When genes involved in flagellum sodium
uptake are mutated, under non-virulence inducing conditions, there CT and TCP production
increased. This suggests a mechanism in which sodium concentration affects virulence gene
expression (lower sodium levels lead to increased virulence gene expression), which would be
an indirect effect of the flagellar action (125). At the strain level using the classical biotype with
the infant mouse model, it has been shown that non-motile strains, in which the genes involved
in flagellar production have been mutated, are able colonize to similar levels as wild-type,
motile strains (120). Similar experiments have been carried out with the El Tor biotype and
have shown opposite results: non-motile mutants were unable to colonize the infant mouse
(126-128). Even with the conflicting data, the current hypothesis is that motility is necessary in
order to penetrate the mucus layer of the small intestine, which, in turn, gives V. cholerae
access to the epithelial cells (40).
Chemotaxis has also been shown to be important for colonization and disease. In the
most general terms, chemotaxis is the movement of an organism either towards or away from a
chemical stimulus. There are three chemotaxis operons in the V. cholerae genome, but only
one that is essential for chemotaxis (129, 130). Like motility, the importance of chemotaxis in
V. cholerae is controversial. In one study, various genes of the El Tor biotype involved in
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chemotaxis were deleted and colonization of the infant mouse intestine was determined. Nonchemotactic mutants colonized the intestine 70-fold better than WT (127). However, the
bacteria were found throughout the intestine, as opposed to only the lower half of the small
intestine corresponding the lower jejunum and ileum, suggesting V. cholerae uses chemotaxis
as a means to find a preferred site for colonization (40).

ToxR Regulon
Transcription of the complex network of virulence genes from both the CTXφ and VPI is
tightly coordinated by a regulatory cascade termed the “ToxR Regulon” (108). Although the
virulence regulon is still often referred to as the ToxR regulon for historical reasons, ToxR is not
the transcriptional regulator of CT and TCP expression, but was simply the first regulator
identified (108, 131). Instead, the coordinated expression of virulence genes is directly
regulated by the transcriptional activator ToxT, and multiple regulatory proteins and factors
affect the cascade to ensure that ToxT is only expressed under optimal environmental
conditions (104, 132-134). ToxR and another transcriptional regulator, TcpP, control
transcription of toxT (135-137). toxR is found in all Vibrio species as part of the ancestral
genome and is constitutively expressed, while tcpP is located on the VPI, and thus found only in
pandemic strains and expressed only under virulence inducing conditions (138-140).
ToxR is an integral membrane regulatory protein homologous with the OmpR family of
proteins that contain a cytoplasmic winged helix-turn-helix DNA-binding domain (141, 142).
ToxS, another integral membrane protein, acts to increase dimerization of ToxR, which is
needed for full ToxR activity in order to then initiate toxT transcription (143, 144). At the toxT
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promoter, it is thought that ToxR acts as an enhancer of TcpP binding as evidence suggests that
although TcpP can interact directly with the RNA polymerase, ToxR is necessary to activate toxT
transcription (145). ToxR/S bind to the toxT promoter between -100 and -69 with respect to the
transcriptional start site as shown by DNase I footprinting in this region (137). ToxR also
regulates transcription of the outer membrane porins OmpU and OmpT. ToxR upregulates
expression of ompU, which encodes a porin that is protective against the negative effects of
bile (146-148). ompU transcription by ToxR is also increased in the presence of bile (149). In
contrast, ToxR downregulates expression of ompT. OmpT is expressed in the environment and
under nutrient limited conditions (150).
TcpP interacts with another membrane protein, TcpH, to regulate transcription of toxT
in combination with ToxR/S (135). TcpP is also a member of the OmpR family of proteins, with
a homologous cytoplasmic domain (142). TcpH is required for the stability of TcpP, as in the
absence of it, TcpP is rapidly degraded by the metalloprotease YaeL (151, 152). In conditions
not permissive for virulence, degradation of TcpP occurs even when TcpH is present (151). YaeL
targets the periplasmic domain of TcpP and is also present in conditions not permissive for
virulence (151). Taurocholate, a bile salt found in the intestine, has been shown to induce
dimerization of TcpP leading to increased activation potential of toxT (153). TcpP/H binds to
the toxT promoter between -51 and -32 relative to the transcriptional start site, and TcpP alone
can activate expression of toxT when over-expressed by relying on its DNA-binding specificity to
locate the promoter (137, 154).
As mentioned previously, tcpPH is not expressed constitutively. Instead, expression of
these genes is dependent on the transcription regulators AphA and AphB (155, 156). AphA
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binds to the tcpPH promoter between -101 and -71, while AphB binds between -78 and -43
(157). AphA is a dimer that is a member of the winged helix transcription factor superfamily
(158), while AphB is a LysR-type regulator protein (155). AphB interacts directly with AphA on
the DNA to activate tcpPH and changes conformation in response to pH and oxygen level
changes (159-161). tcpPH is also negatively regulated by cAMP receptor protein (CRP) and
PepA (131, 157, 162, 163). CRP, normally important in metabolism, can bind to the promoter
and repress expression by competing at the same binding sites as AphA and AphB (157). The
mechanism of PepA repression is still unclear; however it is known that PepA responds to
changes in pH and temperature (162).

Under virulence non-permissive conditions, PepA

represses transcription of tcpPH (162).

Signaling Systems
Quorum sensing is a system used to allow communication between bacteria in order to
change gene expression in response to cell density through the production of small molecules
called autoinducers (164). These autoinducers are constitutively produced so that at low cell
density quorum sensing is turned off due to low concentration of the autoinducers and at high
cell density bacteria sense the presence of autoinducers and alter their gene expression
patterns. V. cholerae uses the system to influence virulence gene expression by downregulating
CT and TCP at high cell density (64, 157, 165, 166). There are three quorum sensing systems in
V. cholerae that control HapR, which in turn, represses transcription of aphA (165, 166). Two
systems are similar, each employing an autoinducer and a sensor kinase. The first system uses
the autoinducer CAI-1 and sensor kinase CqsS, and the second system uses the autoinducer AI-2
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and the sensor kinase LuxQ, with its periplasmic partner LuxP (167). Under low cell density the
kinases phosphorylate LuxU, which in turn transfers the phosphate group to LuxO, and then this
initiates transcription of four small RNAs called qrr1-4 (168, 169). These sRNAs bind to the
5’UTR of HapR mRNA along with Hfq in order to initiate its degradation (170, 171). Under this
condition, there is no HapR and therefore aphA is expressed and virulence gene expression can
occur. Conversely, at high cell density, the autoinducers bind to their respective sensor kinases,
which then act as phosphatases to remove the phosphates from LuxU and LuxO. LuxO now can
no longer activate transcription of qrr1-4 and HapR can then made. With HapR produced, aphA
is now repressed and virulence gene expression is downregulated (165). The third quorum
sensing system uses VarS/VarA proteins in order to activate LuxO (170). VarS/VarA is a twocomponent signaling system that activates CsrB, CsrC, and CsrD, while deactivating CsrA. When
CsrA is inactivated, LuxO can become phosphorylated and act as it does in the other two
systems (170). Even though the direct correlation between quorum sensing and virulence gene
expression seems straightforward, there are some epidemic El Tor strains that have a mutated
hapR that leaves it non-functional, suggesting that quorum sensing is not important for causing
human disease (64). Therefore, more research is needed to fully determine the role that
quorum sensing plays in virulence gene regulation. HapR also controls other genes involved in
virulence expression in addition to aphA such as HapA and VPS operon (172). HapR increases
expression HapA, a hemagglutin/protease involved in mucosal escape in El Tor strains, while in
turn, represses the VPS operon, which is involved in biofilm formation. At low cell density,
biofilms are activated as HapR is not present (173).
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In addition to quorum sensing, V. cholerae is also able to use the second messenger
3’,5’-cyclic diguanylate (c-di-GMP) as part of a signaling system to change gene expression
(174). With this system, c-di-GMP levels are modulated in response to some first messenger
and these different c-di-GMP levels directly correspond to changes on the cell surface (175). Cdi-GMP production is controlled by diguanylate cyclase, and increased levels of c-di-GMP lead
to increased expression of the biofilm VPS genes, extracellular protein secretion system and
mannose sensitive hemagglutinin type IV pilus biogenesis genes (176, 177). Increased levels of
c-di-GMP also correlate to decreased expression of the fla genes involved in the production of
flagella (176, 177). The levels of c-di-GMP are controlled directly by the VieSAB system (178).
VieA is a phosphodiesterase that acts to decrease the levels of intracellular c-di-GMP.
Decreased c-di-GMP expression correlates with maximal CT production (174).

The Virulence Gene Transcription Activator ToxT
ToxT is a 32 kDa, 276 amino acid protein that acts as the main virulence gene regulator
for ctxAB and tcp (104, 132-134). It is a member of the AraC/XylS family of proteins, sharing
homology in the C-terminal domain (CTD) (179-181). The CTD is about 100 amino acids and
contains two helix-turn-helix DNA-binding motifs (179, 181). The N-terminal domain (NTD)
spans amino acids 1-160 and the CTD consists of amino acids 170-276 with a small linker region
of ten amino acids between the two domains (182). The NTD does not share sequence
similarity to other AraC/XylS family members, but the ToxT crystal structure does show some
secondary structural homology to AraC despite having very little amino acid identity (182).
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ToxT not only activates transcription of the genes encoding CT and TCP, but also
activates transcription of other virulence genes including acfA, acfD, aldA, tagA, tcpI, and the
RNAs tarA and tarB (109, 110, 113, 114, 183). To activate these genes, ToxT binds to 13 base
pair degenerate sequences termed toxboxes, each containing a poly-T tract at the 5’ end of the
binding site. Toxboxes are located upstream of the -35 promoter element that is recognized as
part of the RNA polymerase binding site (183). This toxbox location suggests that ToxT must
directly interact with the RNA polymerase α subunits to stimulate transcription (184).
Depending on the particular virulence gene in question, the toxboxes can have different
arrangements. At the promoters of tcpA, ctxAB, and tarA there are two toxboxes arranged as
direct repeats (114, 183). For acfA, acfD, tagA, and tcpI there are two toxboxes arranged as
inverted repeats, with the divergently transcribed acfA and acfD sharing the same toxboxes
(110, 183, 185). In contrast, aldA only contains one toxbox (109). ToxT can also activate its own
transcription through its role in activating transcription of the tcp operon, within which the toxT
gene is located (133, 134). The ability of ToxT to regulate its own expression is thought to allow
for finer control of virulence gene expression.
Members of the AraC/XylS family include some proteins that act as dimers, including
AraC, RhaS, and RegA and some member that act only as monomers, including MarA, SoxS, and
Rob (185-188). The ability of ToxT to act as either a monomer or a dimer at the promoters it
activates has been quite controversial. As most ToxT-activated promoters contain two
toxboxes, it is hypothesized that ToxT acts as a homodimer, but, aldA only has one toxbox
suggesting that ToxT does not require dimerization in order to activate the virulence gene
promoters (109). The NTD of ToxT has been shown to be involved in dimerization through
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studies using the LexA dimerization assay as well as bacterial two-hybrid systems (182, 189192). Interestingly, full length, intact ToxT has never been observed to dimerize and the ToxT
crystal structure is of a monomeric protein. Virstatin, a small molecule inhibitor of virulence
gene expression, has been proposed to act by decreasing ToxT dimerization (192, 193). Other
studies, however, have shown that ToxT can bind to promoters as a monomer, such as at the
tcpA promoter (110, 183). In this experiment, the spacing between the toxboxes was increased
and using DNA-footprinting it was shown that ToxT was still able to protect the DNA (110, 183).
However, when the spacing was greatly altered, ToxT was not able to activate transcription
indicating that the distance between the sites is important for full activation. Even though there
has been extensive work on the dimerization ability of ToxT, more work still needs to be done
to understand its role in ToxT function.

Effectors of ToxT
There are both positive and negative effectors that affect the ability of ToxT to activate
transcription. The histone-like protein H-NS is a global repressor protein of transcription and is
found in many gram-negative bacteria, including V. cholerae (194). H-NS is able to oligomerize
and occupy multiple binding sites near promoters such as ctxAB, toxT and tcpA, where it acts to
repress transcription (195, 196). H-NS has also been shown to compete with ToxT at the ctxAB
promoter, suggesting a mechanism by which H-NS must be displaced by ToxT in order to derepress transcription of the virulence gene it is acting upon (197).
To induce virulence in vitro, different growth conditions are used for the two different V.
cholerae biotypes. For the classical biotype, 30°C, Luria-broth (LB) at pH 6.5, and aeration are
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sufficient for maximal activation of ctxAB and tcp (198). In contrast, for the El Tor biotype, a
biphasic culture condition termed AKI conditions is used for maximal production of CT and TCP.
Under AKI conditions, the culture is grown statically at 37°C in AKI peptone medium for several
hours and then switched to aeration conditions for an additional two hours (199-201). Although
the two conditions differ, they each allow for maximal ToxT production and therefore maximal
CT and TCP production. Another growth condition that was found to result in CT production in
both biotypes was in rich medium containing fresh sodium bicarbonate statically at 37°C (202).
This will be described more below.
While the laboratory growth conditions described above are artificial and do not
resemble conditions that would be present in the human small intestine, effectors of ToxT
activity can be found in the environment that V. cholerae inhabits. Using in vitro conditions has
allowed the elucidation of some of the chemical signals necessary for virulence induction, but
as the small intestine is at 37°C and under static conditions, it is obvious that there must be
certain in vivo signals that allow for virulence production to occur. These include temperature,
pH, and various host chemicals such as bicarbonate and bile (160, 202-205). The chemical
bicarbonate has been shown to be a positive effector of ToxT activation of CT and TCP (202).
Bicarbonate is found in the same place where V. cholerae colonizes to act as a protective buffer
in the small intestine and is secreted by the intestinal epithelial cells (206). Although it does not
increase the production of ToxT, bicarbonate has been shown to increase the ability of ToxT to
activate virulence gene transcription by enhancing DNA binding (202, 207).
Bile, conversely, is a negative regulator of ToxT activity (203-205). Secreted by the gall
bladder, bile contains many different components, including bile salts, saturated and
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unsaturated fatty acids, cholesterol, proteins, and phospholipids that normally act together to
emulsify fats in the lumen of the small intestine and act as a bactericide. When added in vitro to
V. cholerae, bile is shown to cause decreased production of TCP and CT, and increased motility,
biofilm formation, and outer membrane protein quantities (203-205). In one study, bile was
fractionated to determine the components responsible for decreased virulence activation by
ToxT (204). From this information, it was shown that only the unsaturated fatty acid (UFA)
components are responsible for decreased virulence (204). Of the UFA components, oleic,
linoleic, and arachidonic acids are the most abundant UFA components of bile (204). Linoleic
acid, the UFA primarily used in the studies described in this dissertation, is an 18-carbon fatty
acid that contains two cis-double bonds. Upon resolution of the crystal structure of ToxT, cispalmitoleic acid, another UFA, was found buried in the NTD (182). In one study, cis-palmitoleic
acid was only ~0.5% of the total fatty acid content in bile, as compared to oleic acid, which
accounted for ~23.5%, linoleic acid accounted for ~14%, and arachidonic acid accounted for
approximately ~3% of the total UFA content in bile (204). However, this fractionation was done
with ox bile. A similar study in 1987 fractionated the fatty acid components in 24 healthy, adult
human volunteers and found slightly different amounts: ~2.68% for palmitoleic acid, ~12.09%
for oleic acid, ~32.83% for linoleic acid and ~5.64% for arachidonic acid with the rest composed
of saturated fatty acids (208). In this study, linoleic acid composed the largest proportion of
UFA, as opposed to the previous study in which oleic acid accounted for the largest proportion.
The aim of this work is to better understand how V. cholerae responds to a change from
environmental to host conditions. This includes work aimed at identifying the mechanism by
which linoleic acid decreases virulence gene expression by acting through ToxT. Conjugated
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linoleic acid is currently on the market as a weight loss supplement proposed to inhibit fat
absorption and this is also studied as it could potentially be used as either a prophylactic or as a
therapy to reduce CT production and thus disease duration and intensity. In current era in
which antibiotic resistance is becoming a severe problem, therapeutics that inhibit
pathogenesis but do not affect bacterial survival are likely to become much more attractive as
the bacteria are unlikely to develop resistance against them.
A list of all strains used is included in Table 1. Together, this dissertation enhances both
our basic understanding of virulence gene regulation and host signals during cholera and
translates this newly acquired knowledge into a potential cholera therapeutic that is safe for
human consumption and is inexpensive.
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Strain

Plasmid

Description

JW 467

pMAL-c2e-ToxT

Escherichia coli BL21(DE3)

JW 1560

pJW 407

MBP-ToxT for protein
purification

JW 9

Parent
Strain

JW 467

JW 150

Vibrio cholerae classical
strain O395
∆toxt

JW 9

VJ740

∆toxt-helix-turn-helix

O395

JW 18

pJW 54

PtcpA::lacZ in pTL61t

JW 9

JW 441

pJW 211

PctxAB::lacZ in pTL61t

JW 9

JW 87

pJW 82

PaldA::lacZ in pTL61t

JW 9

JW 97

pJW 89

PtagA::lacZ in pTL61t

JW 9

JW 86

pJW 81

PacfA::lacZ in pTL61t

JW 9

JW 89

pJW 84

PacFD::lacZ in pTL61t

JW 9

JW 169

pJW 91

PtcpI::lacZ in pTL61t

JW 9

JW 666

pJW 308

PtoxT::lacZ in pTL61t

VJ740

JW 329

pJW 179

PtcpP::lacZ in pTL61t

JW 9

JW 515

pJW 54

PtcpA::lacZ in pTL61t

JW 150

JW 1809

pJW 211

PctxAB::lacZ in pTL61t

JW 150

JW 167

pJW 82

PaldA::lacZ in pTL61t

JW 150

JW 168

pJW 89

PtagA::lacZ in pTL61t

JW 150

JW 165

pJW 81

PacfA::lacZ in pTL61t

JW 150

JW 166

pJW 84

PacFD::lacZ in pTL61t

JW 150

JW 169

pJW 91

PtcpI::lacZ in pTL61t

JW 150

CRP4

pCRPhis

CRPhis in pBAD33

K2294

O395tcpA::lacZ ∆toxt

JW 150

JW 714
JW 1066

pJW 407

MBP-ToxT

JW 714

JW 1414

pJW 501

MBP-ToxT (G100A)

JW 714

Table 1. List of strains used in this work.

Source

Chapter

New
England
Biolabs
Lab
Collection

1-4

Lab
Collection

1-4

Lab
Collection
(132)

1

Lab
Collection
Lab
Collection
Lab
Collection
Lab
Collection
Lab
Collection
Lab
Collection
Lab
Collection
Lab
Collection
Lab
Collection
Lab
Collection
Lab
Collection
Lab
Collection
Lab
Collection
Lab
Collection
Lab
Collection
Lab
Collection
Lab
Collection
Lab
Collection
Lab
Collection
Lab
Collection

1

1-4

1

1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
2
2
2
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Strain

Plasmid

Description

JW 1415

pJW 502

MBP-ToxT (D101A)

Parent
Strain
JW 714

JW 1416

pJW 503

MBP-ToxT (L102A)

JW 714

JW 1417

pJW 504

MBP-ToxT (M103A)

JW 714

JW 1418

pJW 505

MBP-ToxT (I104A)

JW 714

JW 1419

pJW 506

MBP-ToxT (R105A)

JW 714

JW 1420

pJW 507

MBP-ToxT (N106A)

JW 714

JW 1421

pJW 508

MBP-ToxT (L107A)

JW 714

JW 1422

pJW 509

MBP-ToxT (Y108A)

JW 714

JW 1423

pJW 510

MBP-ToxT (S109A)

JW 714

JW 1424

pJW 511

MBP-ToxT (E110A)

JW 714

JW 1469

pJW 520

MBP-ToxT (L107F)

JW 714

JW 1470

pJW 521

MBP-ToxT (R105K)

JW 714

JW 1471

pJW 522

MBP-ToxT (R105Q)

JW 714

JW 1472

pJW 523

MBP-ToxT (L107S)

JW 714

JW 1474

pJW 525

MBP-ToxT (N106S)

JW 714

JW 1475

pJW 526

MBP-ToxT (N106F)

JW 714

JW 1556

pJW 536

MBP-ToxT (L114A)

JW 714

JW 1582

pJW 538

MBP-ToxT (R105A, N106A)

JW 714

JW 690

O395tcpA::lacZ

JW 9

JW 75

E. coli SM10 λpir

JW 751

pJW316

PtcpA::gfp

JW 690

JW 422

pFD1

mariner transposon

JW 75

JW 947

∆pckA

JW 690

JW 939

∆pepcase

JW 690

JW 940

∆icd

JW 690

pckA in pBAD33 in ∆pckA

JW 947

JW 1125

pckA

Table 1 cont. List of strains used in this work.

Source

Chapter

Lab
Collection
Lab
Collection
Lab
Collection
Lab
Collection
Lab
Collection
Lab
Collection
Lab
Collection
Lab
Collection
Lab
Collection
Lab
Collection
Lab
Collection
Lab
Collection
Lab
Collection
Lab
Collection
Lab
Collection
Lab
Collection
Lab
Collection
Lab
Collection
Lab
Collection
Lab
Collection
Lab
Collection
Lab
Collection
Lab
Collection
Lab
Collection
Lab
Collection
Lab
Collection

2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
3
4
4
4
4
4
4
4

24
CHAPTER ONE
The mechanism for inhibition of ToxT activity by the unsaturated fatty acid components of bile
in Vibrio cholerae
ABSTRACT
The gram-negative curved bacillus Vibrio cholerae causes the severe diarrheal illness
cholera. During host infection, a complex regulatory cascade results in production of ToxT, a
DNA-binding protein that activates the transcription of major virulence genes that encode
cholera toxin (CT) and toxin-coregulated pilus (TCP). Previous studies have shown that bile and
its unsaturated fatty acid (UFA) components reduce virulence gene expression. Bile is likely an
important chemical recognized by V. cholerae upon entering the host. However, the
mechanism for the bile-mediated reduction of TCP and CT expression has not been defined.
There are two likely hypotheses for this effect: 1) UFAs decrease DNA binding by ToxT or 2)
UFAs decrease dimerization of ToxT. To determine whether bile/UFAs affect DNA binding by
ToxT, we first determined that UFAs, specifically linoleic acid, can enter V. cholerae when added
exogenously. We then performed electrophoretic mobility shift assays with ToxT on various
virulence promoters in the presence or absence of UFAs. The results indicate that UFAs can
enter the bacteria, where they can then interact with ToxT in the cytoplasm to decrease ToxT
binding to DNA even at a promoter having only one ToxT binding site. This suggests a
mechanism in which UFAs do not affect dimerization but can affect monomeric ToxT binding to
DNA.
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INTRODUCTION
V. cholerae, a gram-negative curved bacillus possessing a single polar flagellum, is the
causative agent of cholera. Cholera is a diarrheal disease contracted by consuming
contaminated food or water and is characterized by severe diarrhea that leads to dehydration,
and can ultimately cause death if left untreated. Each year, there are an estimated 1.4-4.3
million cholera cases and 20,000-142,000 deaths from the disease (14, 15). In order to cause
disease, V. cholerae must colonize the duodenum, where it is able to express its virulence genes,
including the most important of these: toxin co-regulated pilus (TCP) and cholerae toxin (CT).
TCP is required for intestinal colonization, while CT is responsible for the massive secretion of
electrolytes and water into the lumen, causing diarrhea. These virulence genes and others are
regulated by the major virulence transcription activator ToxT.
Virulence gene expression is regulated by what is historically known as the ToxR regulon
(108, 131). toxT transcription is activated by two sets of inner membrane proteins, ToxR/ToxS
and TcpP/TcpH, that bind upstream of toxT, as well as by a ToxT positive feedback loop (133137). ToxT is a 32-kDA member of the AraC/XylS transcriptional regulator family, having a
conserved 100-amino-acid DNA binding domain, consisting of two helix-turn-helix motifs, in its
C-terminal domain (CTD). Located upstream of all ToxT-activated genes are 13-bp degenerate
DNA sequences called toxboxes that vary in configuration at individual genes (110, 114, 183185). ToxT directly controls transcription of genes encoding not only TCP and CT, but also other
accessory virulence genes including acfA, acfD, aldA, tagA, tarA, tarB, and tcpI (109, 110, 113,
114, 183). Except for the aldA promoter, in which there is a single toxbox, there are two
toxboxes present at ToxT-activated promoters (109, 110, 114, 183, 185). ToxT can bind to single
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toxboxes as a monomer but it is thought that full activation only occurs upon ToxT dimerization
on the DNA, at least at some genes (110, 183). The ToxT N-terminal domain (NTD), does not
share significant sequence homology with other proteins, but has some structural similarity to
the AraC NTD, which is the domain necessary for AraC dimerization and arabinose binding
(182). NTDs of ToxT have been shown to interact when separated from the CTD, although the
true role of dimerization in ToxT function is not fully understood (109, 182, 189-193).
A number of host and environmental factors affect ToxT activity, including temperature,
pH, bile and bicarbonate (160, 202-205). Bile is produced by the liver and then subsequently
stored in the gallbladder. Upon eating, bile is released into the duodenum where it acts to
solubilize lipids. Bile itself is a complex, heterogeneous mixture that includes bile salts,
cholesterol, bilirubin, and saturated and unsaturated fatty acids (UFAs). V. cholerae encounters
bile early during infection and it is proposed to be a natural effector of ToxT as it is found in the
same places that V. cholerae colonizes (203-205). V. cholerae has reduced virulence gene
expression in the presence of bile and/or UFAs, with increased motility gene expression, biofilm
formation, the induction of efflux pumps, and increased amounts of outer membrane proteins
OmpU, OmpT and TolC (146, 203, 204, 209-211). Bile and its UFA components have been
previously shown to decrease CT and TCP production, but the mechanism of this effect on
virulence gene expression levels is not understood (203, 204). Bile also has another role, in that
it is able to act as a bactericide for the benefit of the host, but enteric bacteria, such as V.
cholerae, are not only adapted to live in the presence of bile, but potentially can recognize bile
as a signal to ensure survival in the host (203, 205). Another negative regulator of ToxT is
virstatin, which is a small, synthetic molecule that has been previously shown to decrease ToxT

27
activity (192, 193). The mechanism for this has been proposed to be by inhibiting ToxT
dimerization (192). Whether UFAs and virstatin inhibit ToxT activity via the same mechanism is
unknown.
In this study we show that UFAs, specifically the unsaturated fatty acid linoleic acid, are
able to enter the bacterial cell where ToxT is also present in the cytoplasm. We report that
linoleic acid and virstatin cause decreased transcription of ToxT-controlled virulence genes and
determined that the mechanism by which this happens is decreased binding affinity at ToxTactivated promoters, regardless of the number or configuration of the toxboxes. Our results
indicate that UFAs decrease ToxT binding to DNA even at promoters having one ToxT binding
site, suggesting a mechanism in which UFAs do not only affect the ability of ToxT to dimerize,
but also affect the ability of monomeric ToxT to bind to DNA. These results give us a clearer
understanding of the regulatory networks controlling virulence gene expression during human
infection.
MATERIALS AND METHODS
V. cholerae strains and growth conditions. All V. cholerae strains used in the study are
derived from classical biotype O395. Strains were maintained in Luria Broth (LB) containing
20% glycerol and stored at -70°C. All promoter::lacZ fusions used for β-galactosidase assays
were made in plasmid pTL61T as described in previous studies (202, 207). Overnight cultures
were grown for ~16 hours at 37°C in LB and then diluted 1:40 into LB pH 6.5 at 30°C for
virulence inducing conditions in the presence or absence of freshly prepared .05% bile (sodium
choleate), 160µM linoleic acid, or 100µM virstatin. V. cholerae strains were grown with
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antibiotic concentration of 100µg/mL streptomycin and strains with the plasmid pTL61T were
grown with 100µg/mL ampicillin.
Western blot analysis of ToxT. Immunodetection of ToxT was performed using the
same procedure as previously described (202). Briefly, bacteria were harvested after inducing
conditions either DMSO only, 160µM linoleic acid, or with 100µM virstatin.

Cells were

normalized at an optical density of 600nM and resuspended in 2x protein buffer. Samples were
then boiled, separated by 14% SDS-PAGE, blotted, and blocked for 30 minutes in TBS buffer.
After blocking, the blots were incubated overnight in a 1:2,500 dilution of rabbit polyclonal antiToxT serum, washed three times in TBS buffer, and secondary goat anti-rabbit IgG conjugated
to alkaline phosphatase (AP) was used at a dilution of 1:5000 (Southern Biotech). Blots were
washed again and then developed using immune-BCIP (MP Biomedicals).
14

C linoleic acid uptake and fractionation. V. cholerae classical biotype strain O395 was

grown overnight in LB at 37°C, subcultured 1:40 in LB pH 6.5, and grown for two hours in the
absence of linoleic acid. At two hours, 0.1μCi

14

C-radiolabeled linoleic acid (58.2mCi/mmol)

(Perkin-Elmer) was added for each milliliter of the subculture. Upon addition of the
radiolabeled linoleic acid, 1 mL of the culture was immediately centrifuged, and the
supernatant saved to compare to cell pellet cpms. The cell pellet was washed 3 times with 1 mL
of PBS and centrifuged each time. Cell pellets were resuspended in 100μL PBS and added to
5mL Scintillation cocktail (Fisher Scientific). The same procedure was followed for other aliquots
of the subculture at times 5, 15 and 30 minutes. After uptake, cpm was measured for each time
point using an LS6000IC liquid scintillation counting system (Beckman).
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14

C linoleic acid fractionation assay. After overnight growth, V. cholerae O395 classical

biotype was subcultured 1:40 in the absence of linoleic acid. After 2 hours, 0.1μCi

14

C-

radiolabeled linoleic acid (58.2mCi/mmol) (Perkin-Elmer) was added to one milliliter of the
subculture and incubated at room temperature. After one hour, the bacteria were harvested by
centrifugation and washed three times in PBS. Bacteria were then resuspended in 20mM TrisHCl, pH 8.5 and 500 mM NaCl) and freeze-thawed in an ethanol and dry ice bath, then thawed
at 37°C. This process was repeated for a total of three freeze-thaw cycles. The bacteria were
then fractionated by centrifugation for 10 min at 15,000 x g to separate the
periplasm/membrane and cytoplasm.

A Western Blot was performed to ensure efficient

fractionation (data not shown). The cytoplasm was taken as the supernatant and the pellet was
resuspended in PBS. Each fraction was then measured for cpm of each fraction using a LS6000IC
liquid scintillation counting system (Beckman).
β-galactosidase assays. Strains to be analyzed were grown overnight in LB at 37°C and
then subsequently subcultured 1:40 into LB pH 6.5 in the presence or absence of 160µM
linoleic acid dissolved in DMSO. Cultures were grown under virulence inducing conditions
(aeration at 30°C) for 3 hours and then analyzed.

The β-galactosidase assay was then

performed following the same established protocol (212).
qRT-PCR. As in previous assays, after overnight growth, V. cholerae classical biotype
O395 was subcultured 1:40, either with or without 160µM linoleic acid. RNA from three
biological samples in each condition was extracted using the RNeasy Bacteria Protect Mini Kit
(Qiagen) and manufacturer’s protocols were followed. DNA contamination was removed using
an on-column RNase-free DNase kit (Qiagen) and confirmed free of DNA by the absence of
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bands using logarithmic PCR. To measure the relative mRNA levels of tcpA and aldA the
following primers were used: forward tcpA (5’-ACGCAAATGCTGCTACACAG-3’) reverse tcpA (5’CCCCTACGCTTGTAACCAAA-3’), and forward aldA (5’-TTGGTGGGCATCCTAACAAT-3’) reverse
aldA (5’-ACACCGGCACCTAAACCATA-3’). qRT-PCR was performed using one-step SYBR green
Mastermix (Invitrogen) and the following program: cDNA synthesis for 10min. at 55° C,
denaturing step for 5min. at 95° C, followed by 35 cycles of 95° C for 10 s, then 55° C for 30 s.
The level of each mRNA was normalized to the level of rpoB using primers forward rpoB (5’ACCTGAAGGTCCAAACATCG-3’) and reverse rpoB (5’-CAAAACCGCCTTCTTCTGTC-3’). Relative
levels of transcript with the addition of linoleic were calculated using 2 -ΔΔCT and analyzed
comparing the ΔΔCT values as previously described (213).
Protein Purification. Maltose binding protein-ToxT fusion (MBP-ToxT) and MBP-CRP
purification was performed as previously described using E. coli strain BL21(DE3) with the
plasmid pMAL-c2E carrying either MBP-ToxT or MBP-CRP (207, 214). Briefly, after MBP-ToxT or
MBP-CRP induction by IPTG, cells were lysed by French press, run over an amylose column, and
fractions containing MBP-ToxT or MBP-CRP were saved and dialyzed into 50mM Na2HPO4 (pH
8.0), and 100mM NaCl and then dialyzed into the same solution containing 20% glycerol to save
as freezer stock at -80° C.
Electrophoretic mobility shift assays (EMSA) and binding curve analysis. EMSAs were
performed as previously described (214). Purified MBP-ToxT, or MBP-CRP with cAMP (New
England Biolabs), was incubated with DNA probes made by PCR from the promoter sequence of
interest using one primer radiolabeled with γ-32P (Perkin-Elmer) by T4 polynucleotide kinase
(New England Biolabs). Binding reactions contained various amounts of MBP-ToxT with
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constant 10 µg/mL salmon sperm DNA as nonspecific competitor, 10mM Tris-acetate (pH 7.4),
1mM Potassium EDTA (pH 7.0), 100mM KCl, 1mM dithiothreitol (DTT), 0.3mg/mL bovine serum
albumin (BSA) and 10% glycerol in a volume of 30µL. To each reaction, a constant concentration
of the labeled DNA probe was added. In reactions containing linoleic acid, the final
concentration was 32µM for each reaction, and for reactions containing virstatin, the final
concentration was 50µM, except at the aldA promoter where a higher concentration of 100µM
was used. All other reactions contained 3.33% (1μL in 30μL) DMSO as a solvent control. Binding
reactions were incubated for 30 minutes at 37°C and then loaded into a 6% polyacrylamide gel
at 4°C. Gels were dried for 1 hour and then analyzed by autoradiography.
Binding curve analysis. Autoradiographs were analyzed using ImageJ software (NIH) as
previously described with nonspecific binding omitted from further analysis (207). Briefly, to
determine the Kd for samples containing either linoleic acid or virstatin and compared to
protein bound to DNA without inhibitor, the percent of protein bound with labeled DNA was
determined

for

each

lane.

This

was

then

fit

to

the

equation

%Bound=Bmax*[Protein]h/(Kdh + [Protein]h) with Bmax constraint set to 100 using Graphpad Prism
5 software. The Kd values for each condition were compared to each other using the extra sum
of squares F test to determine if the two values were statistically different.
RESULTS
ToxT protein is produced in the presence of linoleic acid. Previous work has
demonstrated that UFAs inhibit virulence gene expression by acting through ToxT (204). Oleic
acid has been previously shown to negatively regulate TCP and CT expression levels (182). In
preliminary experiments, we determined that linoleic acid had the strongest negative effect on
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ToxT activity of several different UFAs tested (data not shown), and previous studies have
shown that linoleic acid makes up the largest proportion of unsaturated fatty acid content in
human bile (208). To date, direct interaction of linoleic acid and ToxT has not been observed,
although a palmitoleic acid molecule was visualized within the ToxT NTD in the solved crystal
structure (182). To begin our study, we investigated whether ToxT protein production was
affected by the addition of linoleic acid in the media. It had been previously determined that
there are comparable levels of toxT expression in cultures grown with and without linoleic acid
(204). To confirm this, we analyzed the β-galactosidase production from a toxT::lacZ reporter
plasmid in V. cholerae grown in the presence or absence of linoleic acid (Figure 1A). When V.
cholerae was grown under virulence-inducing conditions (LB pH=6.5, aeration) in the presence
of linoleic acid, the amount of β-galactosidase activity indicated that there was no statistically
significant difference (P=.799) in toxT expression whether the culture had linoleic acid or lacked
it. This is consistent with previous data confirming that linoleic acid does not
affect toxT transcription.
To further examine the effect of linoleic acid on ToxT, and confirm that there were no
effects of linoleic acid on translation, we carried out Western blot analysis to assess the ToxT
protein levels (Figure 1B). V. cholerae was grown under virulence-inducing conditions in the
presence or absence of linoleic acid and cell extracts were harvested. ToxT-specific polyclonal
antibodies were used to detect protein levels. No differences in ToxT levels were observed
regardless of the presence or absence of linoleic acid, as a ToxT-specific band was visible in
Western blots at the same intensity under both conditions (Figure 1B, lanes 4 and 5). This band
was not detected in the ΔtoxT control strain (Figure 1B, lane 3). Thus, ToxT was stably
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produced regardless of the presence of linoleic acid while bacteria were grown under virulenceinducing conditions.
Linoleic acid enters the V. cholerae cytoplasm. As ToxT protein levels were roughly
equivalent with or without linoleic acid, we next assessed whether a direct interaction between
linoleic acid and ToxT would be possible. Such an interaction would require that linoleic acid be
imported into the bacterial cytosol. To determine whether this occurs, we performed an uptake
assay using radiolabeled linoleic acid (Figure 2). V. cholerae was subcultured under virulenceinducing conditions for two hours and then

14

C-labeled linoleic acid was added to the culture.

Aliquots of the culture were taken at times 0, 5, 15, and 30 minutes after addition of
radiolabeled linoleic acid and radioactivity was quantified by a scintillation counter. The amount
of radioactivity found in the cell pellet was compared to the supernatant. Results from this
assay show that linoleic acid enters the bacteria at a linear rate with a best-fit line equation of y
= 3421.3x + 30974 and an R2-value of .969.
These data, however, do not indicate whether linoleic acid is present inside the
bacterium or simply associated with the cell surface or outer membrane. To determine whether
linoleic acid enters the cytosol,

14

C-labeled linoleic acid was added to V. cholerae cultures

grown under virulence-inducing conditions and then the bacteria were fractionated into
membrane and cytoplasmic portions. This allowed us to see where in the bacterium linoleic
acid was localized: the membrane, the cytoplasm, or both. Cultures were incubated for one
hour with the radiolabeled linoleic acid. These cultures were then pelleted and washed and the
bacteria were separated into a cytoplasm and envelope fraction by multiple freeze-thaw cycles.
The 14C-linoleic acid in each fraction was then quantified using a scintillation counter. Results of
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this experiment show that most of the linoleic acid is able to enter the cell (Figure 3). Directly
comparing the amounts of linoleic acid in the two fractions showed that about 65% of the total
14

C-linoleic acid was present in the cytoplasmic fraction, while 35% was present in the

membrane fraction. These data suggest that a significant fraction of extracellular linoleic acid
can enter the cytosol, where it could then interact with ToxT.
Linoleic acid decreases ToxT activation of virulence gene transcription. tcpA and ctxAB
expression have been previously shown to be inhibited by the addition of oleic acid to the
media, but the effects of linoleic acid were not assessed in those studies (182). We assessed
whether the inhibitory effect of linoleic acid that we observed extended to a variety of ToxTactivated promoters with various ToxT binding site (toxbox) configurations, including tcpA,
ctxAB, acfA, aldA, acfD, tagA, and tcpI. All of these promoters contain two toxboxes in either
direct (tcpA, ctxAB) (183) or inverted repeat configurations (acfA, acfD, tagA, tcpI) (110, 183,
185) except for aldA, which contains only one toxbox (109). Plasmid-borne promoter-lacZ
fusions were added to the wild-type V. cholerae classical strain as well as an otherwise isogenic
ΔtoxT strain to measure transcriptional activity at these promoters with and without 160µM
linoleic acid (Figure 4). At each of these promoters, linoleic acid had a statistically significant
negative effect that prevented ToxT from fully activating transcription at the promoters in wildtype O395. No effect of linoleic was observed in the ΔtoxT strain, confirming that linoleic acid
acts through ToxT (Figure 4).
As the aldA promoter activity even in the absence of linoleic acid was much lower than
at the other promoters, we performed quantitative real-time PCR (qRT-PCR) to compare
expression levels of this promoter to expression levels of the tcpA promoter upon the addition
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of linoleic acid. Bacteria were cultured using the same methods as the β-galactosidase assay
and then the RNA was extracted. qPCR was then performed using primers for tcpA, and aldA,
while using rpoB as the housekeeping gene control. The qPCR results showed that both tcpA
and aldA were downregulated upon the addition of linoleic acid to the media (Figure 5). tcpA
mRNA levels were lower when grown with linoleic acid, showing a mean fold decrease of 58.7
and aldA levels decrease by a fold change of 28.4.
There is decreased ToxT-DNA binding affinity with the addition of linoleic acid. To
determine if linoleic acid is able to directly affect ToxT binding to DNA at the ToxT-activated
promoters, we used EMSA. This method allows the binding pattern of ToxT to be characterized
and give an estimation of the equilibrium dissociation constant, Kd, which represents the
concentration of ToxT required for binding 50% of the DNA at equilibrium. The K d values with
and without linoleic acid will give a direct comparison of the effect of the fatty acid on the given
promoter, as a higher Kd value indicates a lower binding affinity of ToxT for the DNA and a
lower Kd value indicates higher binding affinity.
To begin, we used the primary promoter in the tcp operon, PtcpA, as our 32P-labeled DNA
probe. Using purified MBP-ToxT, we added increasing amounts of protein to binding reactions
with either DMSO alone (Figure 6A, lanes 1-7) or 32μM linoleic acid dissolved in DMSO
(Figure6A, lanes 8-14) and a constant concentration of labeled DNA probe. Binding reactions
were brought to equilibrium, and then run on a 6% polyacrylamide gel, followed by
autoradiography. Densitometry analysis was performed using ImageJ software to calculate the
percentage of bound DNA at each concentration of MBP-ToxT. A binding curve was made for
each set of reactions to determine the percentage of bound DNA at each concentration of MBP-
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ToxT using Graphpad software (Figure 6B). In the case of MBP-ToxT binding to PtcpA DNA, the Kd
without linoleic acid was 10.0nM and the Kd with linoleic acid was 33.1nM. These values are
significantly different, and as the Kd with linoleic acid is greater than without, this indicates a
lower ToxT binding affinity for PtcpA in the presence of linoleic acid. These data suggest there is
likely a direct interaction between linoleic acid and ToxT as exhibited by the decreased binding
affinity.
To confirm that linoleic acid does not generally inhibit protein-DNA interactions, we
used cyclic AMP receptor protein (CRP) as a control, together with the region upstream of tcpP
as described above. We performed an EMSA comparing CRP binding with and without the
addition of linoleic acid (Figure 6C) and performed densitometric analysis to determine the
binding curves and Kd values. The binding curve and Kd values were statistically the same for
CRP binding to PtcpP with or without linoleic acid (Figure 6D).
We then wanted to determine the binding curves and Kd values at other ToxT-activated
promoters, as there can be different toxbox orientations (Figure 7). As the equilibrium binding
experiments on PtcpA showed a decrease in DNA binding upon addition of linoleic acid, we
wanted to determine whether this occurred at promoters having alternative toxbox
configurations, particularly at PaldA, which has only one toxbox (Figure 7.) If linoleic acid can
decrease the binding affinity of ToxT for PaldA, it could indicate a mechanism other than UFAs
interrupting ToxT dimerization (189). The PctxAB contains two directly repeated toxboxes like
PtcpA, albeit in the opposite direction and having different spacing distance (214). The rest of the
ToxT-activated promoters previously mentioned, PacfA, PacfD, PtagA, and PtcpI each contain
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toxboxes oriented in inverted repeat configuration as well as various spacing between the
toxboxes (110, 183, 185).
As linoleic acid was shown earlier to decrease promoter activity for all of these ToxTactivated promoters, we determined whether linoleic acid also affected the binding affinity
using EMSA with each promoter region as described above. For P ctxAB, containing direct repeats,
the Kd without linoleic acid is 4.44nM, and with linoleic acid is 10.1nM, indicating decreased
binding affinity of ToxT (Figures 7A,B). As an example of an inverted repeat promoter, we chose
to look at PtagA. Here, densitometry and binding curve analysis again revealed decreased
binding affinity of ToxT for the promoter upon the addition of linoleic acid, with a K d of 4.078nM
without linoleic acid, and 27.8nM with linoleic acid (Figures 7C,D). Lastly, we examined ToxT
binding to the single toxbox promoter of aldA. Figure 7E shows the autoradiograph of ToxT
binding to PaldA with and without linoleic acid. The Kd once again was increased going from
11.3nM without linoleic acid to 48.67nM with linoleic acid (Figure 7F). These data, along with
the previously described decrease in promoter activity with the addition of linoleic acid as
indicated by the β-galactosidase assays, suggest that linoleic acid decreases binding at each
promoter regardless of toxbox configuration and spacing.
Another negative ToxT effector, virstatin, acts differently than linoleic acid. The results
above suggest a direct negative effect of linoleic acid on ToxT binding to DNA. We next
examined whether this was also true for another negative ToxT regulator, virstatin. Previous
studies suggested that virstatin negatively affects the ability of ToxT to dimerize (192). To begin,
we looked at ToxT levels using Western blot analysis to compare V. cholerae grown with or
without virstatin (Figure 1, lanes 6 and 7). The ToxT levels were unchanged, confirming that
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ToxT production is not affected by virstatin. We then performed β-galactosidase assays on the
previously described ToxT-regulated genes to assess the effects of virstatin (Figure 8). These
data show decreased ToxT activity at all promoters except for aldA, where virstatin had no
significant effect. Previous work had suggested that the aldA promoter was affected by virstatin
(192). We then performed EMSAs to determine whether virstatin affected the DNA binding
ability of ToxT at tcpA, ctxAB, and aldA, as representatives of the different toxbox
configurations (Figure 9). Virstatin decreased binding at tcpA and ctxAB through analysis of the
binding curve and Kd, (Figures 9A-D) but did not decrease ToxT binding at the aldA promoter
even at a higher concentration of virstatin (Figure 9E). In fact, the K d significantly decreased
from 21.83nM to 11.79nM with the addition of virstatin, indicating a higher binding affinity of
ToxT at the aldA promoter when virstatin is present (Figure 9F).
DISCUSSION
The activation of virulence gene expression relies on the transcriptional activator, ToxT,
active in mucus layer of the small intestine where V. cholerae colonizes. Previous studies have
looked at the involvement of bile, UFAs, and virstatin on V. cholerae virulence gene expression
and ToxT dimerization (182, 192, 193, 203-205). Most of this work with negative effectors has
been done only on tcpA and ctxAB; here, in addition to these genes, we also look the effects of
negative effectors on ToxT activity at aldA, acfA, acfD, tagA, and tcpI. All ToxT-controlled
promoters showed a decrease in expression in the presence of linoleic acid. Prior to entry into
the mucus layer of epithelial cells and colonization, V. cholerae must pass through the lumen of
the small intestine where high concentrations of bile and UFAs are present. Linoleic acid needs
to be taken up by V. cholerae and enter the cytoplasm in order to directly interact with ToxT.
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Here, we show that linoleic acid is able to enter the cell and that the majority of it enters the
cytoplasm.
Much work has been done previously on the effect of these negative effectors on
virulence gene expression, but their direct effect on ToxT DNA binding affinity had not been
previously assessed. It has been proposed that the mechanism of action for virstatin and UFAs
is inhibition of ToxT dimerization (189, 192). The binding sites for ToxT, toxboxes, and their
configurations have been extensively studied, but whether toxbox configuration factors into the
inhibition of ToxT activity by linoleic acid had not been examined. Here we show that the
decrease in binding affinity in response to linoleic acid can be seen at each ToxT-activated
promoter that we examined, regardless of toxbox configuration. This suggests that linoleic acid
has a general effect on DNA binding by ToxT monomers. Previous work strongly suggested that
ToxT binds to DNA as a monomer (109, 110, 183) and that ToxT does not behave as a typical
dimeric activator, such as AraC.
We also looked at virstatin and its method of action on ToxT. A previous study examined
virulence gene promoter activity in the presence of virstatin; however, unlike this earlier study,
the effect of virstatin in our hands was not as pronounced. We did observe that virstatin
significantly decreased promoter activity to a lessened extent (Figure 8,(192)). While
Shakhnovich et al. saw, at greatest, 20% promoter activity in the presence of virstatin at the
aldA, acfA, and tcpI promoters, we observed a decrease, but not to that extent. Interestingly,
we did not see any effect of virstatin on ToxT activation at the single toxbox, aldA promoter
with the β-galactosidase assay (Figure 8). In this same regard, virstatin also did not have an
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effect on the ability of ToxT to bind the aldA promoter (Figures 9E,F). In contrast, we did see a
negative effect of linoleic acid at the aldA promoter on both ToxT-dependent virulence gene
promoter activity (Figure 4) and ToxT binding affinity, where the Kd increased from 11.25nM to
48.67nM (Figures 7E,F).
These data suggest that virstatin and linoleic acid, although both negative effectors of
virulence, do not have the same mechanism for downregulating gene expression. Another
study performed bacterial two-hybrid assays to look at the effect of various UFAs on
dimerization and the data suggest another UFA, oleic acid, does affect ToxT dimerization (204).
However, linoleic acid was not tested and this study was done using only the NTD of ToxT
instead of intact, full-length ToxT, whose dimerization has never been experimentally observed,
at least in published reports. More testing using full-length ToxT in V. cholerae with this twohybrid system in the presence of linoleic acid would confirm whether or not linoleic acid is
involved in dimerization. As there was reduced binding of ToxT at the aldA promoter, it is likely
that linoleic acid changes the structural conformation of ToxT, leading to inhibited DNA binding.
This will be further explored in Chapter Two of this dissertation.
Understanding the effect of host signals on bacterial pathogenesis is useful for complete
understanding of the V. cholerae virulence cascade, as many host signals are used by the
bacteria to sense the appropriate location in which virulence gene transcription should be
initiated. When passing through the small intestine, V. cholerae encounters many different
chemical signals, such as bile and bicarbonate, which either inhibit or activate ToxT-dependent
gene transcription. Bile and its UFA components are at high concentrations in the duodenal
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lumen, in which ToxT is inactive (191, 204, 205, 215). Once the mucus layer is penetrated, UFA
concentration decreases, while the bicarbonate concentration increases. At this point, along
the epithelial surface, ToxT becomes active and V. cholerae can colonize. UFAs such as linoleic
acid likely keep ToxT in a form unable to bind tightly to DNA in the lumen, because production
of TCP would lead to bacterial aggregation and colonization of the epithelial surface would
become impossible. In this model, V. cholerae is able to use both negative and positive
effectors of virulence in order to colonize in its ideal niche. Our findings here show a direct
effect of linoleic acid on ToxT, giving useful insight into the mechanisms of ToxT gene
regulation.
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a)

b)

FIGURE 1. Effect of linoleic acid on PtoxT::lacZ and ToxT expression. (A). Light gray bars, wildtype V. cholerae grown without linoleic acid; dark gray bars, wild-type V. cholerae grown with
64µM linoleic acid. Statistical significance was determined by Student's t test. (B). Effect of
linoleic acid and virstatin on ToxT protein levels. V. cholerae was grown under virulence
inducing conditions (LB pH 6.5, 30°C, aeration) with DMSO, linoleic acid or virstatin (lanes 4, 5,
6). Purified full length ToxT-6His migrates to ~32kDa (lane 2) and a ΔtoxT strain shows no band
(lane 3) were used as controls. Samples were normalized by OD 600. The Western blot was
probed with anti-ToxT antibody. This is representative of three separate experiments.
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FIGURE 2. C14-radiolabeled linoleic acid is taken up by V. cholerae. Classical strain O395 cells
were grown under virulence-inducing conditions for two hours and then the radiolabeled
linoleic acid was added at time 0 and analyzed at times 5, 15, and 30 minutes post-addition,
measured as CPM per optical density unit at 600nm. The equation of best fit is y = 3421.3x +
30974 and an R2-value of .969

44

Fractionation
80

*

Percent

60
40
20
0
% Envelope

% Cytoplasm

FIGURE 3. C14-radiolabeled linoleic acid is able to enter the cell and enter the cytoplasm. After a
2-hour subculture in virulence-inducing conditions, linoleic acid was added to the culture and
allowed to sit for one hour. After one hour, V. cholerae was fractionated into an envelope and
cytoplasmic portion by multiple freeze-thaw cycles. There is significantly more linoleic acid in
the cytoplasmic portion as compared to the envelope portion. Error bars represent +/- standard
error mean and statistical significance was determined by Student's t test, *, p<.05
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FIGURE 4. The negative effect of linoleic acid on various ToxT-activated promoters. Cultures
***p<.0005
were grown under virulence-inducing conditions with or without 160μM linoleic acid. βgalactosidase activity produced from plasmid-borne virulence gene promoter fusion constructs
in either wild-type or isogenic ΔtoxT. Statistical significance determined using Student’s t-test
(*, p < 0.005; **, p<.0005). Error bars represent +/- standard error mean.
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FIGURE 5. qRT-PCR data of tcpA and aldA comparing cultures grown with and without linoleic
acid. Both transcripts were expressed less with the addition of linoleic acid. However there is a
greater effect of linoleic acid on tcpA as compared to aldA. Data shown as the negative fold
change of the inverse of the 2-ΔΔCT value. Statistical significance determined using Student’s ttest (*, p<.05; **, p<.005).
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FIGURE 6. Linoleic acid decreases binding affinity of MBP-ToxT to PtcpA. MBP-ToxT binding to
PtcpA was analyzed using EMSA. (A) Binding reactions between MBP-ToxT and PtcpA in lanes 1-7
were conducted in the absence of linoleic acid. Lanes 8-14 were incubated in the presence of
32μM linoleic acid. Lanes 1 and 8 contained PtcpA DNA in the absence of MBP-ToxT. Subsequent
lanes contained a titration of MBP-ToxT with concentrations labeled in the figure. (B) Binding
curve for the autoradiograph shown in (A). Densitometry of autoradiograph was performed
with ImageJ software. Circles represent percent PtcpA bound by MBP-ToxT in the absence of
linoleic acid. Solid line corresponds to the binding curve for MBP-ToxT. Squares and dashed line
represent percent bound and binding curve, respectively, in the presence of linoleic acid. (C)
Autoradiograph of EMSA showing titration of MBP-CRP bound to PtcpP with DMSO (Lanes 1-7)
and linoleic acid (Lanes 8-14). (D) Binding curves with and without linoleic acid with K d.
Autoradiographs of EMSAs presented are representative of three or more independent
experiments. Kd for each condition is inset and significant difference between the best-fit values
of each data set is denoted by * (p< 0.0001).

48

a)

b)
100

Alone
Linoleic Acid (32M)

%PctxAB Bound

80
60
40
20
0
0.1

Kd
1

10

Alone
4.436

Linoleic Acid (32M)
10.05*

100

[ToxT] nM

d)

c)

% PtagA Bound

100

Alone
Linoleic Acid (32M)

80
60
40
20
0
0.1

Kd
1

10

Alone
4.078

Linoleic Acid (32M)
27.78*

100

[ToxT] nM

e)

f)

% PaldA Bound

100

Alone
Linoleic Acid (32M)

80
60
40
20
0
0.1

Kd
1

10

[ToxT] nM

100

Alone
11.25

Linoleic Acid (32M)
48.67*

49

FIGURE 7. Linoleic acid decreases binding affinity of MBP-ToxT at other virulence promoters. In
all radiographs, binding reactions in lanes 1-7 are with DMSO only, while lanes 8-14 are in the
presence of 32μM linoleic acid. (A), (C), (E) are autoradiographs showing MBP-ToxT binding at
Pctx, PtagA, and PaldA respectively. (B), (D), (F) are the binding curves corresponding to each
autograph: Pctx, PtagA, and PaldA respectively. All autoradiographs and binding curves are
representative of at least three separate experiments. Kd for each condition is inset and
significant difference between the best-fit values of each data set is denoted by * (p< 0.0001).
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FIGURE 8. The effect of virstatin on ToxT-regulated virulence gene promoters. Cultures were
grown under virulence-inducing conditions with and without virstatin. Promoter activity with
and without 100μM was compared, and at all promoters except for aldA, virstatin caused a
significant decrease in promoter activity. Statistical significance determined using Student’s ttest (**, p<.005; ***, p<.0005).
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FIGURE 9. Virstatin decreases binding affinity of MBP –ToxT at PtcpA and Pctx, but not at PaldA. In
all radiographs, binding reactions in lanes 1-7 are with DMSO only, while lanes 8-14 are in the
presence of virstatin. 50µM virstatin was used for (A) and (C) and 100µM for (E). (A), (C), (E) are
autoradiographs showing MBP-ToxT binding at PtcpA, Pctx, and PaldA respectively. (B), (D), (F) are
the binding curves corresponding to each autograph: P tcpA, Pctx, and PaldA respectively. All
autoradiographs and binding curves are representative of at least three separate experiments.
Kd for each condition is inset and significant difference between the best-fit values of each data
set is denoted by * (p< 0.0005).
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CHAPTER TWO
A small unstructured region in Vibrio cholerae ToxT mediates the response to negative effectors
ABSTRACT
V. cholerae is the causative agent of the severe diarrheal disease cholera. A complex
network of transcriptional and post-transcriptional regulators controls production of the
virulence factors that are required for human disease. ToxT is the transcription regulator that
directly controls the production of the two major virulence factors: toxin co-regulated pilus
(TCP) and cholera toxin (CT). The solved crystal structure of ToxT revealed an unstructured
region in the N-terminal domain between residues 100 and 110. This region and the
surrounding amino acids have been previously implicated in ToxT proteolysis, resistance to
inhibition of virulence induction by negative effectors, and ToxT dimerization. To better
characterize this region, site-directed mutagenesis was performed to assess the effects of bile
and its unsaturated fatty acid (UFA) components on ToxT sensitivity. This analysis identified
specific mutations within this unstructured region that limit the inhibition of virulence gene
activation by bile and unsaturated fatty acids. These results suggest that a small unstructured
region in the ToxT N-terminal domain is involved in virulence gene regulation and response to
human host signals.
INTRODUCTION
V. cholerae is the etiological agent of the severe diarrheal disease, cholera. Cholera
disease is characterized by extreme water loss and dehydration due to diarrhea, and if left
untreated can result in death. The bacteria are usually ingested through contaminated food or

54
water and colonize the upper small intestine (44). When the V. cholerae bacterium is in the
optimal environment within the intestine, it begins producing the major virulence factors
responsible for causing disease: cholera toxin (CT) and toxin co-regulated pilus (TCP) (100, 101,
198). CT is an ADP-ribosylating toxin composed of five binding B subunits and one enzymatic A
subunit (216). After binding the GM1 ganglioside via the B subunits, the A subunit is
translocated into the intestinal epithelial cell, where it modifies G sα1, leading to aberrant
secretion of chloride, water, and other electrolytes (8). TCP is a type IV bundle-forming pilus
responsible for bacteria-bacteria interactions that result in microcolony formation during
intestinal colonization (99, 101, 217).
TCP and CT are produced via a virulence regulatory cascade known as the ToxR regulon.
Expression of CT and TCP is directly activated by the major virulence transcription regulator,
ToxT (104, 133). ToxT binds “toxbox” motifs in the promoters of ctxAB and tcpA, as well as in
the promoters of other accessory virulence factors, such as acfA, acfD, tagA, aldA, and tcpI, and
small regulatory RNAs tarA and tarB, resulting in expression of these genes under appropriate
conditions (109, 110, 113, 114, 133, 134, 183, 196). ToxT is a 276 amino acid protein that is part
of the AraC/XylS family of transcription regulators (180). ToxT consists of two domains, the Nterminal domain (1-160) (NTD) and the C-terminal domain (170-276) (CTD), separated by a
short linker (161-169) (182). The CTD comprises the DNA-binding domain, consisting of two
helix-turn-helix motifs, which has sequence similarity with the AraC/XylS family (181). The NTD
shares no significant sequence similarity with any other protein, but shares secondary
structural similarity with AraC (182) despite having only 14% identity at the amino acid level.
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Transcription of toxT is initially activated by both TcpP/H and ToxR/S (104, 135-137).
After ToxT protein is present, it can produce more of itself independently of TcpP/H and ToxR/S
by binding to the promoter of tcpA and activating transcription of a long, polycistronic mRNA
containing toxT (134, 136). Proteolysis of ToxT is required to break this auto-regulatory loop
and completely shut off virulence gene expression prior to escape from the host (218). A region
of the ToxT NTD between amino acids 100-109 was found to be required for proteolysis of ToxT
(218). This region was not resolved in the ToxT crystal structure, indicating the absence of a
fixed structure, at least in ToxT crystals (182).
Activation of ToxT-dependent promoters is further regulated by effector molecules that
act on ToxT. ToxT activity is inhibited by bile and, to a greater extent, the unsaturated fatty acid
(UFA) components of bile, including oleic, linoleic, and arachidonic acid (204, 205). The ToxT
crystal structure contained a buried 16-carbon fatty acid, palmitoleic acid, which was shown to
decrease binding of ToxT to the tcpA promoter when added exogenously (182). Another
inhibitor of ToxT, virstatin, decreases ToxT activation of ctxAB and tcpA by presumably
inhibiting ToxT dimerization (192, 193). On the other hand, ToxT activity is enhanced by
bicarbonate, which is abundant within the upper small intestine where V. cholerae colonizes
(202). Given their high concentrations in the upper small intestine, bile and bicarbonate are
likely to be in vivo effectors used by V. cholerae to determine the optimal location for
colonization.
In the solved ToxT crystal structure, a region between amino acids 100-109 was not
visible, indicating that it lacked a consistent structure, at least in the context of the crystal. This
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unstructured region was shown to contain the site critical for proteolysis (218), and, together
with the surrounding amino acids, has also been implicated in responding to bile, unsaturated
fatty acids (UFAs), and virstatin (189, 190, 210). Due to its importance for ToxT proteolysis and
sensing of ToxT inhibitory substances, we performed site-directed mutagenesis on this
unstructured region and the surrounding amino acids to identify specific amino acid changes
that alter ToxT function. Mutational analysis of amino acids 100-110 confirmed that this region
is important for control of ToxT proteolysis. We have further identified specific mutations that
prevent the ToxT effectors bile and its UFA components from affecting ToxT activity. These
results suggest that the unstructured region in the ToxT NTD plays a central role in control of V.
cholerae virulence by impacting ToxT activity at multiple levels.
MATERIALS AND METHODS
Bacterial Strains and Growth Conditions. Escherichia coli JM101 was used for cloning.
All strains were maintained at -70°C in LB containing 20% glycerol. For determination of
response to negative effectors, overnight cultures of classical O395 V. cholerae were diluted
1:40 into LB pH 6.5 in the presence or absence of 0.05% sodium choleate (Sigma-Aldrich) as a
substitute for crude bile and 32 μM linoleic acid (Acros Organics). Cultures were grown shaking
for 3 hours at 30°C and analyzed. Induction of protein expression from pMAL-c2e derivatives in
all of these conditions was done using a final concentration of 25μM isopropyl-β-Dthiogalactopyranoside (IPTG).
Plasmid and strain construction. Construction of site-directed ToxT mutants was done
using splicing by overlap extension PCR (219). For cloning C-terminal His-tagged toxT into
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pBAD33, outside primers BP22 and BP195 (218) were paired with inside primers containing
desired mutations using V. cholerae O395 toxT as a template. PCR products were inserted into
pBAD33 using restriction enzymes XbaI and PstI. For cloning MBP-ToxT, outside primers BP171
and BP172 (218) were paired with inside primers and PCR products were inserted into the
pMAL-c2e vector using restriction enzymes KpnI and PstI. pBAD33 and pMAL-c2e derivatives
were electroporated into a previously constructed V. cholerae classical biotype strain O395
∆toxt mutant with a chromosomal tcpA::lacZ fusion (202).
β-galactosidase assays. Cells were grown under the appropriate conditions and βgalactosidase activity was measured and expressed in Miller units as previously described (202,
212, 218, 220).
Protein purification and electrophoretic mobility shift assays (EMSA). Protein
purification and EMSAs were performed as previously described (214). Maltose-binding protein
(MBP) fusions were purified from E. coli BL21(DE3) with plasmid pMAL-c2e containing either
MBP-ToxT WT or MBP-ToxT N106F. DNA probes for EMSA were produced by PCR of plasmid
pTL61t containing PtcpA. Binding reactions were performed in 30uL total volume containing 10
μg/mL salmon sperm DNA, 10 mM Tris-acetate (pH 7.4), 1 mM Potassium EDTA (pH 7.0), 100
mM KCl, 1 mM dithiothreitol (DTT), 0.3 mg/mL bovine serum albumin (BSA) and 10% glycerol,
along with titrations of MBP-ToxT WT or N106F. Binding reactions were performed in the
presence of 32 μM linoleic acid for 30 minutes at 37°C, and run through a 6% polyacrylamide
gel at 4°C. Binding reactions for comparison to linoleic acid reactions contained 3.33% DMSO.
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Binding curve analysis. Autoradiographs were analyzed using ImageJ software (NIH) as
previously described (data submitted for publication). Briefly, the percent of labeled DNA
bound by MBP-ToxT WT or N106F was determined for each lane and Graphpad Prism 5
software was used for curve fitting to the equation %Bound=Bmax*[Protein] h/(Kdh + [Protein]h)
with Bmax constraint set to 100. The Kd for each condition was calculated and significance of Kd
between conditions was determined.
RESULTS
Identification of ToxT residues involved in responding to natural negative effectors,
bile and linoleic acid. The crystal structure of ToxT revealed a small, unstructured region in the
NTD of the protein (182). This region, as well as the surrounding amino acids, has been
implicated in ToxT proteolysis, resistance to negative effectors of ToxT activity, and
dimerization (190-193, 215, 218). To further characterize this region in regard to these roles, we
performed site-directed alanine mutagenesis of ToxT amino acids 100-110, shown in Figure 10.
The unstructured region of ToxT has previously been shown to have residues that are required
for normal response of ToxT to bile and UFAs (189, 191). Bile and UFAs decrease the ability of
ToxT to activate transcription of virulence genes (204, 205). Two ToxT mutations, M103A and
N106A, have previously been described as insensitive to bile and UFAs (189). We tested strains
carrying these ToxT mutations, as well as strains carrying other alanine substitutions in the
unstructured region, to determine whether their response to these negative ToxT effectors was
altered. Overexpression of ToxT eliminates the effect of bile and linoleic acid on ToxT activity.
Therefore, we chose to use the IPTG-inducible expression vector pMAL-c2e in place of
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arabinose-inducible pBAD33 to easily decrease the overall production of ToxT, and to facilitate
protein purification for downstream applications. Previous work that used MBP-ToxT fusions
showed no significant difference in activity as compared to untagged ToxT (205). As a further
control for any effect the MBP tag may have had on ToxT activity, we also performed
experiments with untagged ToxT mutants of interest and found that they respond to effector
molecules similarly to MBP fusions using the pMAL-c2e vector (data not shown). The MBP-ToxT
mutants were induced from pMAL-c2e in a ΔtoxT derivative of classical biotype V. cholerae
strain O395 containing a chromosomal tcpA::lacZ transcriptional fusion. Induction of tcpA
transcription in the presence and absence of negative effectors was measured by βgalactosidase reporter assay and used as a metric for ToxT activity. The fold change upon
addition of effector molecules was calculated for each individual experiment. The mean fold
change for each mutant was determined and will be referred to as ToxT’s response to effectors.
Significance of the fold change of each ToxT mutant compared to the fold change of WT ToxT in
response to negative effectors was determined using a Student’s t-test.
Figure 11A shows the activity and response of the ToxT mutants to 0.05% sodium
choleate, a crude derivative of bile. 0.05% sodium choleate was the lowest concentration that
still decreased ToxT activity in titration experiments (data not shown). Alanine mutations to
amino acids 100-104, 107, and 108 caused reductions in overall activity of ToxT in the presence
and absence of bile as compared to WT MBP-ToxT. These results agree with previous reports
that mutations at these residues reduce activation of acfA::phoA (190). The L107A mutation
completely eliminated tcpA::lacZ expression. Prior reports have suggested that this mutation
inhibits ToxT dimerization and therefore inhibits ToxT activity (189, 190). Additionally, ToxT
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R105A had higher overall activity compared to WT, as has been previously reported (190). The
fold decrease in activation of tcpA::lacZ upon addition of bile was calculated for each mutant
(Figure 11A). This analysis revealed ToxT mutations (G100A, D101A, I104A, Y108A, and E110A)
that caused a greater sensitivity to the negative effect of bile. The M103A mutation did not
affect the sensitivity of ToxT to bile as compared to WT, which was unexpected as this mutant
reportedly had decreased sensitivity to bile when measuring CT and TCP production (189).
However, a mutation at amino acid 106, which had been previously shown to decrease
sensitivity to bile when measuring CT and TCP production (189) also decreased sensitivity to
bile in our work.
The ability of these ToxT mutants to activate tcpA::lacZ in the presence or absence of 32
μM linoleic acid was also assessed (Figure 11B). As was observed in the bile experiments,
mutation to residues 100-104, 107, and 108 caused decreased overall transcriptional activity
with and without added effector. Also, mutants D101A, M103A, I104A, and Y108A had
increased sensitivity to linoleic acid, as we had observed with bile. Previous work suggested
that the M103A ToxT mutant has diminished sensitivity to another UFA, palmitoleic acid (189).
However, we observed increased sensitivity of M103A to the negative effector linoleic acid.
Mutant N106A, which was previously reported to cause a reduced response to palmitoleic acid
in terms of CT and TCP production (189), also exhibited decreased activation of tcpA::lacZ in the
presence of linoleic acid, verifying the importance of this residue for the response to negative
effectors. Interestingly, this mutant also showed decreased sensitivity for addition of bile as
well as bicarbonate, a positive effector of ToxT, (data not shown). These results suggest that the

61
same ToxT residues within the unstructured region may be involved in both positive and
negative effectors.
Alternate substitutions in the ToxT unstructured region affect response bile and UFAs.
The results described above show that alanine mutagenesis within the unstructured region of
ToxT alters the protein’s sensitivity to bile and unsaturated fatty acids. Because amino acids
mutated to alanine in the unstructured region showed reduced sensitivity to both bile/UFA and
bicarbonate, we generated alternate substitutions of amino acids 105 (as it showed less
sensitivity to bicarbonate, data not shown) and 106 to further investigate the role of these
residues in ToxT function. We also made mutations to amino acid 107 because the L107A
mutant was completely inactive and a previous report showed that mutation L107F had
decreased response to bile (191). Finally, we made an alanine substitution of amino acid L114,
which has been shown to cause insensitivity to the inhibitory effects of bile, UFAs, and virstatin
and is located in close proximity to the 100-109 unstructured region (189, 193). ToxT mutants
R105K, R105Q, R105F, N106S, N106F, L107F, L107S, L114A, and a double mutant R105A/N106A
were tested using the β-galactosidase assay described above in bile/linoleic acid inhibiting
conditions (Figures 12A,B). Fold change with addition of effectors was calculated for each
mutant and compared to the fold change response of WT ToxT.
Alternate substitutions at amino acid R105 generally exhibited higher than normal ToxT
activity in the absence of effector molecules, similar to what was observed after mutation to
alanine. ToxT R105Q had increased response to the negative effector bile, while ToxT R105F
exhibited a decreased response to bile (Figure 12A). On the other hand, ToxT R105K exhibited
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increased sensitivity to linoleic acid (Figure 12B). The increased sensitivity to negative effectors
of the R105K and R105Q mutants may be due to a conformational change in the protein that
increases accessibility of the negative effector binding sites. ToxT L107F, which has previously
been reported as having decreased response to bile and UFAs (191), had increased response to
both negative effectors compared to WT. ToxT L107S was similar to L107A in having inactivity.
ToxT N106S had a response to bile similar to WT, while the double mutant R105A/N106A had
decreased sensitivity to bile, presumably due to the N106A mutation (Figure 12A). The N106S
mutation caused an increase in response to linoleic acid, but the double R105A/N106A mutant
displayed reduced sensitivity to linoleic acid (Figure 12B). L114A was insensitive to bile and
UFAs as previously described (189). Another mutation, N106F, revealed complete insensitivity
to the negative effectors, bile and linoleic acid. This is a novel mutation that exhibits greatly
decreased response to negative effectors.
Change in binding affinity of ToxT N106F is reduced in presence of the linoleic acid.
Previous work has suggested that palmitoleic acid decreases the ability of ToxT to bind to PtcpA
(182). Additionally, we have shown that linoleic acid decreases the binding affinity of ToxT to
virulence gene promoters regardless of toxbox orientation (Chapter One). To assess the ability
of linoleic acid to alter the binding affinity of ToxT N106F to PtcpA, we subjected WT MBP-ToxT
and the N106F derivative to electrophoretic mobility shift assays (EMSA). Experiments were
designed to determine the equilibrium binding affinity of ToxT for the major virulence gene
promoter, PtcpA, in the absence and presence of effector. DNA was added to binding reactions at
a concentration below the estimated Kd along with a titration of MBP-ToxT.
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A representative autoradiograph containing the titration of WT MBP-ToxT binding in the
absence (Lanes 1-6) and presence of 32 μM linoleic acid (Lanes 7-12) is shown in Figure 13A.
Binding reactions in the absence of linoleic acid contained a volume control of DMSO. The
binding curves for each condition were generated using Graphpad Prism 5 software and the
equation %Bound=Bmax*[MBP-ToxT]h/(Kdh + [MBP-ToxT]h). From this equation, the equilibrium
binding affinity, Kd, was determined and significance was calculated (Figure 13B). The Kd of WT
ToxT for PtcpA was increased with linoleic acid, corresponding to a decrease in binding affinity.
The MBP-ToxT N106F mutant was also assessed for changes in Kd in the presence of linoleic
acid. The EMSA and resulting binding curve for reactions containing linoleic acid revealed no
significant change in Kd when compared to the DMSO control (Figures 13C,D). The lack of
change in binding affinity of ToxT N106F with the addition of these ToxT effector molecules
correlates with the transcriptional reporter assays described above (Figures 12,13D), providing
a direct link between changes in DNA binding and transcriptional activation.
DISCUSSION
ToxT is the major transcription activator that induces CT and TCP production and thus is
responsible for initiating cholera disease. It has previously been shown that amino acids in the
region of 100-110 of ToxT are important for the response to negative effector molecules and
dimerization (189-193). Also, this region was required for ToxT proteolysis (218). Interestingly,
this region was not visible in the solved ToxT structure due to the absence of a fixed structure in
ToxT crystals (182). We discovered amino acids important for the response of ToxT to bile and
linoleic acid including N106A, R105A/N106A, N106F, and L114A, which all showed decreased
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sensitivity to the effector when mutated. These same amino acid substitutions were also
important in the response to the positive effector bicarbonate (data not shown). Most
mutations to amino acid 105 had no effect on reducing the response to bile and linoleic acid,
but have been shown to have reduced sensitivity to bicarbonate (data not shown). Additionally,
effector-insensitive ToxT N106F demonstrated no change in binding affinity to PtcpA in response
to UFA and bicarbonate.
The negative effectors of ToxT activity, bile, UFAs, and virstatin, have been implicated in
reducing dimerization of ToxT monomers, leading to reduced overall activity (189, 192). We
hypothesize that negative effector binding forces ToxT into an inactive conformation that could
be due to decreased interaction between ToxT monomers through the unstructured region,
similar to has been previously proposed based on the ToxT crystal structure (182). The
unstructured region of ToxT is a likely candidate for effector molecule binding due to its
importance in the response to negative and positive effectors, solvent accessibility (182) for
on/off binding, and its disorder in the crystal structure. Unstructured regions in crystal
structures are often disordered due to the lack of a stabilizing molecule (221), which could also
be the case with ToxT. It is unlikely that UFAs directly bind the unstructured region of ToxT, as
mutations in the region do not reverse the proteolytic blockade by linoleic acid, but it is
hypothesized that the positive effector bicarbonate could bind in this region. Previous findings
in our lab revealed that the addition of linoleic acid blocked proteolysis of ToxT, but the UFAinsensitive ToxT N106F did not reverse the effect of linoleic acid on ToxT proteolysis (data not
shown). Therefore, we conclude that amino acid N106 is not part of a binding site for UFAs,
agreeing with results from (182). The unstructured region is likely to be important for the
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change in ToxT structure, mediated by linoleic acid binding, which results in lower DNA binding
affinity.
We have previously introduced a model wherein ToxT becomes activated by
bicarbonate as the concentration of bicarbonate increases when V. cholerae enters the mucus
layer of the small intestine (202). This model posits that ToxT is in an inactive form in the lumen
of the intestine due to a lower local concentration of bicarbonate. The model was expanded in
(222), where bile/UFAs in the lumen of the intestine inactivate ToxT, and are replaced by
bicarbonate as the bacterium moves closer to the mucus/epithelial layer. Using this model of
ToxT-dependent virulence in the host, it is plausible that the inactive state of ToxT with UFA
bound can be converted to the active state in the presence of enough bicarbonate, even
though the effectors may not bind in the same region. After ToxT is produced and V. cholerae is
in the lumen of the intestine, ToxT must remain intact but inactive so that CT and TCP are not
produced prematurely in infection. UFAs in bile provide a mechanism for ToxT inactivity in the
lumen and also protect ToxT from proteolysis. As the bacteria encounter higher concentrations
of bicarbonate and lower concentrations of UFA closer to the epithelial surface, bicarbonate
binds and converts ToxT to its active conformation.
In this model, shown in Figure 14, we propose that when ToxT is produced under
virulence inducing conditions it is in fluctuation between an active and inactive conformation in
the absence of effector molecules. This fluctuation leads to mid-level virulence promoter
activity. In the presence of negative effector molecules, ToxT becomes locked into an inactive
conformation, resulting in low virulence gene promoter activity. In this conformation, it is
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proposed that the NTD and CTD are pulled together by the effector molecule (182), and we add
that this conformation impedes access to the unstructured region by the ToxT protease. This
conformation could also inhibit ToxT dimerization. Alternatively, in the presence of the positive
effector molecule bicarbonate, ToxT is locked into an active conformation, causing the highest
virulence gene promoter activity. We propose that the active conformation of ToxT has an
exposed unstructured region that leads to a high degree of proteolysis.
In summary, we determined that an unstructured region in the NTD mediates the
response of ToxT to negative effectors present in the intestine. This unstructured region plays a
role in the response of ToxT to environmental signals and has implications for the temporal and
spatial regulation of virulence factor production in the host
Work performed in the chapter is all my own; however, most of the text is from a
manuscript with Joshua Thomson.
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FIGURE 10. Linear representation of ToxT domain orientation and mutagenesis sites. Amino
acids located in the unstructured region (UR) of ToxT between amino acids 100-110 were
mutated to alanine for initial analysis of region. N-terminal domain (NTD) located between 100160; Linker (L) located between 160-169; C-terminal domain (CTD) between 170-276. Helixturn-helix domains 1 and 2 (HTH1,HTH2) located within the CTD.
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FIGURE 11. Effect of MBP-ToxT alanine mutagenesis in response to negative effectors, bile and linoleic
acid. V. cholerae O395 ΔtoxT mutant with plasmid-borne WT or MBP-ToxT mutants were grown under
virulence-inducing conditions with or without the addition of negative effectors for 3 hours. (Top) Light
gray bars, V. cholerae grown (A) without bile or (B) with dimethyl sulfoxide (DMSO) alone; dark gray
bars, grown with (A) 0.05% bile or (B) 32μM linoleic acid dissolved in DMSO. β-galactosidase produced
from chromosomal tcpA::lacZ in classical strain O395 ΔtoxT. Statistical significance of ToxT mutant
activation of tcpA::lacZ in each condition compared to WT ToxT activation of tcpA::lacZ in the same
condition was calculated using Student’s t-test. Statistical significance of activation by ToxT mutants
without effector denoted by *, with effector by + (*, +,p<0.05). (Bottom) Mean fold-decrease in
activation of tcpA::lacZ upon addition of (A) 0.05% Bile or (B) 32μM linoleic acid for each ToxT mutant.
Statistical significance of fold change MBP-ToxT mutant compared to WT MBP-Toxt was determined by
Student’s t-test (*,P<0.05; **,P<0.01). Horizontal dashed line represents fold-change with addition of
effector of WT ToxT. ToxT mutants above line have increased sensitivity to effector, while below line
represents decreased sensitivity to effector. WT, wild type. Error bars represent +/- standard error of
the mean (SEM).
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FIGURE 12. Alternate substitutions of unstructured region of ToxT affect response to negative
effectors. V. cholerae O395 ΔtoxT mutant with plasmid-borne WT or mutant MBP-ToxT were
grown in the absence and presence of negative effectors. (Top) (A) β-galactosidase produced in
absence and presence of 0.05% bile. (B) β-galactosidase produced in dimethyl sulfoxide (DMSO)
or 32μM linoleic acid dissolved in DMSO. β-galactosidase produced from chromosomal
tcpA::lacZ in classical strain O395 ΔtoxT. Statistical significance of ToxT mutant activation of
tcpA::lacZ in each condition compared to WT ToxT activation of tcpA::lacZ in the same condition
was calculated using Student’s t-test. Statistical significance of activation by ToxT mutants
without effector denoted by *, with effector by + (*, +,P<0.05). (Bottom) Mean fold-decrease in
activation of tcpA::lacZ upon addition of effector shown for each ToxT mutant. Statistical
significance of fold change MBP-ToxT mutant compared to WT MBP-Toxt was determined by
Student’s t-test (*,P<0.05; **P,<0.01). Horizontal dashed line represents fold-change with
addition of effector of WT ToxT. ToxT mutants above line have increased sensitivity to effector,
while below line represents decreased sensitivity to effector. WT, wild type. Error bars
represent +/- standard error of the mean (SEM).
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FIGURE 13. MBP-ToxT N106F has no change in binding affinity to PtcpA after addition of linoleic
acid. MBP-ToxT WT and N106F binding to PtcpA was analyzed using EMSA. Autoradiographs of
EMSAs presented are representative of three or more independent experiments. (Left) Binding
reactions between (A) MBP-ToxT WT or (B) MBP-ToxT N106F and PtcpA in lanes 1-7 took place
with the addition of DMSO. Lanes 8-14 were incubated in the presence of 32 μM linoleic acid.
Lanes 1 and 8 contained PtcpA DNA in the absence of MBP-ToxT. Subsequent lanes contained a
titration of MBP-ToxT with concentrations labeled in the figure. (Right) Binding curve for the
autoradiograph shown to the left. Densitometry of autoradiograph was performed with ImageJ
software. Circles represent percent PtcpA bound by MBP-ToxT in the absence of linoleic acid.
Solid line corresponds to the binding curve for MBP-ToxT to PtcpA determined by the equation
%Bound=Bmax*[Protein]h/(Kdh + [Protein]h) with Bmax constraint set to 100 using Graphpad
Prism 5 software. Squares and dashed line represent percent bound and binding curve,
respectively, in the presence of linoleic acid. Kd for each condition is inset and significant
difference between the best-fit values of each data set is denoted by * (P < 0.00025).
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FIGURE 14. Model for effector control of ToxT activity. In the absence of effector molecules,
there is mid-level transcriptional activation of ToxT and it is in fluctuation between inactive and
active conformations. When bicarbonate is present, ToxT is at high-level transcriptional
activation. The ToxT conformation has increased binding affinity to toxboxes but also leaves the
unstructured region (UR) (proposed to contain a proteolytic cleavage site) accessible by
protease. This conformation resembles ToxT mutants N106F and L114A. Conversely, when
negative effectors are present, ToxT is in an inactive conformation where it has low-level
transcriptional activation. The UR is inaccessible in this conformation, so the site is inaccessible
to protease.
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CHAPTER THREE
The use of conjugated linoleic acid as a potential cholera therapeutic
ABSTRACT
The severe diarrheal disease cholera is currently endemic in over 50 countries. Although
much work has been done to develop effective vaccines against the causative agent, V.
cholerae, these vaccines are currently only effective for very limited amounts of time and do
not offer complete protection. Linoleic acid has been shown to be an effective negative
regulator of V. cholerae virulence, not by killing the bacteria as an antibiotic would, but instead
by acting on the major virulence transcriptional regulator protein, ToxT, to inhibit virulence
gene expression. ToxT activates transcription of the two major virulence factors required for
disease, cholera toxin (CT) and toxin co-regulated pilus (TCP). A conjugated form of linoleic acid
(CLA) is currently sold on the market as a dietary supplement to aid in weight loss, is considered
safe by the US Food and Drug Administration, and is relatively inexpensive. This study examines
using CLA as a new potential prophylactic or as a therapy to reduce CT and TCP production,
which, in turn, would decrease disease duration and intensity.
INTRODUCTION
Cholera is a devastating diarrheal disease that affects between 1.4-4.3 million people
each year causing between 28,000-142,000 deaths (14, 15). The disease is characterized by
severe dehydration that leads to organ shutdown and eventual death if not treated rapidly. It is
caused by the gram-negative curved rod V. cholerae when a person ingests large quantities of
contaminated water or raw shellfish colonized with V. cholerae. Current treatment is oral
rehydration solution as specified by the World Health Organization, containing various salts and

73
glucose to rehydrate as well as replenish electrolytes (3). Without treatment, survival is
approximately 50%, but rehydration with ORS bring survival to greater than 99% (8). Antibiotics
are a treatment option; however their use is limited. By the onset of cholera symptoms, the
bacteria are already being shed back into the environment, but antibiotics can act to slightly
shorten the duration of disease symptoms. As only 25% of people show symptoms when
infected with V. cholerae, the other 75% are still able to shed bacteria into the environment,
potentially for another person to ingest (6, 7).
V. cholerae is classified based on the O antigen of its lipopolysaccharide, and though
there are over 200 serogroups in the environment only one serogroup, O1, has been associated
with pandemics (1, 8, 16). The O1 serogroup can be divided into two biotypes: classical and El
Tor. V. cholerae has caused seven pandemics, and of these, the classical biotype was the
causative agent of the first six, while the El Tor biotype caused the most recent, ongoing
seventh pandemic (8, 16). The classical biotype also causes a more severe disease, but El Tor is
thought to survive better in the environment, although the reasons for this are not understood
(16, 17). O139, another serogroup, emerged in the early 1990s as being involved in outbreaks
(18-21). As such, some refer to these outbreaks as an eighth pandemic (18).
Much work has been done on the development of effective vaccines. There are two oral
vaccines currently available, each with questionable efficacy (28, 29). Neither vaccine is licensed
in the United States due to their lack of complete and long-term protection. The first vaccine,
Dukoral, consists of killed whole V. cholerae cells of both biotypes of serogroup O1 and the B
subunit of CT. It has had very different success in field trials, including a trial in Peru involving
over 17,000 people where the vaccine only offered 15% protection in persons aged six and up
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after one year of surveillance (223). The now preferred vaccine is called Shanchol and it is
composed of both O1 and O139 serogroups. Disappointingly, this vaccine also showed only 45%
protection in all age groups after one year (224, 225). As over half the deaths due to cholera
are in children under five (226), a vaccine that effective in small children is essential. Dukoral,
actually offered negative protection in a field trial in Peru during the first year of surveillance,
and Shanchol only offered 17% protection (223-225, 227). Clearly, more effective vaccines are
necessary.
In order to initiate disease, production of two virulence factors is necessary: CT and TCP.
CT is an A-B5 toxin responsible for the profuse watery diarrhea, while TCP is necessary for host
colonization. The genes encoding both of these virulence factors are both under control of the
major transcriptional activator, ToxT (104, 132-134). V. cholerae encounters high
concentrations of bile and its unsaturated fatty acid components, such as linoleic acid, in the
small intestine before entering the mucosal layer where it is eventually able to colonize (42-44).
In the presence of these negative ToxT effectors, V. cholerae expresses its motility genes, but its
virulence inducing genes are not expressed, as ToxT is not active (40, 41).
To activate the transcription of CT and TCP, ToxT binds to their respective promoters on
binding sites known as toxboxes (183). Linoleic acid can decrease virulence gene expression by
directly reducing the ability of ToxT to activate these promoters (Chapter 1). Currently, CLA is
sold over the counter as a weight loss supplement aimed at inhibiting fat absorption. As it is
relatively cheap and easily accessible, we propose that CLA could potentially be used as either a
cholera prophylactic or as a therapy used in conjunction with oral rehydration to reduce disease
length and intensity by reducing virulence gene production. As antibiotic resistance is becoming
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a more and more concerning problem, using a therapy that can inhibit pathogenesis, but not
bacterial survival, is becoming much more attractive. Here, we show that CLA is able to
downregulate virulence gene expression by acting on ToxT. We also show the effect of CLA in
two animal models: the infant mouse model, which measures the ability of V. cholerae to
colonize and the rabbit ileal loop model, which is used to measure disease by looking at CTdependent fluid accumulation in a rabbit intestinal loop.

MATERIALS AND METHODS
V. cholerae strains and growth conditions. All V. cholerae strains used in the study are
derived from classical biotype strain O395.

Strains were maintained in Luria Broth (LB)

containing 20% glycerol and stored at -70°C. Overnight cultures were grown overnight at 37°C
in LB and then subcultured 1:40 into LB pH 6.5 at 30°C for three hours for virulence inducing
conditions in the presence or absence of 32 or 128µM CLA dissolved in DMSO, or in later
experiments, 640µM of ME-CLA, or 32 µM of one of the three common isoforms of CLA:
9E,11E-; 9Z,11E-; or 10E,12Z- (Sigma-Aldrich). V. cholerae strains were grown with antibiotic
concentration of streptomycin at 100µg/mL.
β-Galactosidase and CT assays. β-galactosidase activity was measured using the basic
procedure of Miller (212). CT was detected in the culture supernatant by a GM1 enzyme-linked
immunosorbent assay (ELISA) (228), using polyclonal anti-CT antibody (Sigma). Briefly, for both
assays, bacteria were grown with or without CLA, CLA-ME or one the CLA isoforms for three
hours under virulence-inducing conditions and then analyzed. DMSO was used as a solvent
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control. A positive control assay for quantification of the level of CT in the samples was
performed using purified CT (List Biological Laboratories).
Electrophoretic mobility shift assays (EMSA) and binding curve analysis. EMSAs were
performed as previously described (214). Purified MBP-ToxT (described previously), was
incubated with DNA probes made from the promoter sequence of interest that had previously
been inserted into the plasmid pTL61T and labeled with γ-32P (Perkin-Elmer) by T4
polynucleotide kinase (New England Biolabs). Binding reactions contained various amounts of
MBP-ToxT with constant 10 µg/mL salmon sperm DNA, 10mM Tris-acetate (pH 7.4), 1mM
Potassium EDTA (pH 7.0), 100mM KCl, 1mM dithiothreitol (DTT), 0.3mg/mL bovine serum
albumin (BSA) and 10% glycerol in a volume of 30µL. To each reaction, a constant concentration
of the labeled DNA probe was added. In reactions containing CLA, the final concentration was
32µM for each reaction. All other reactions contained 3.33% (1μL in 30μL) of DMSO as a solvent
control. Binding reactions were incubated for 30 minutes at 37°C and then loaded into a 6%
polyacrylamide gel to be run at 4°C. Gels were dried for 1 hour and then analyzed by
autoradiography.
Binding curve analysis. Autoradiographs were analyzed using ImageJ software (NIH) as
previously described. Kd values were determined for each binding curve and then the Kd for
each condition were compared to each other using the extra sum of squares F test to
determine if the two values were statistically different.
Infant mouse colonization assays. 5 day old CD1 mouse pups were inoculated with
approximately 106 V. cholerae strain C6706 (El Tor) by oral gavage in a total volume of 50 l.
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CLA, if given, was administered at the time of initial gavage and boosted twice at hours 2 and 4
post-infection. 20 hours post infection the pups were sacrificed, their intestines dissected and
homogenized using a bead beater, and serial dilution of the intestinal homogenate were plated
to enumerate V. cholerae.
Infant mouse colonization assays. Infant mouse assays were performed as previously
described (114). Briefly, 5 days old CD1 mouse pups were inoculated with ~10 6 V. cholerae
classical strain O395 in 50 l total volume, containing 0.5% Evans Blue as a tracer, by oral
gavage. Mice treated with CLA were given either 5% or 10% CLA by volume in 10% Kolliphor
RH40 or 10% Kollidon 25 as a carrier at the time of inoculation. These mice were also boosted
with the indicated concentration of CLA at 3 hr and 6 hr post inoculation. At 20 hr postinfection the mice were sacrificed, dissected, and intestines homogenized using a bead beater.
Intestinal homogenates were serially diluted and plated on LB agar containing 100 g/ml
streptomycin for the enumeration of colonizing V. cholerae.
Rabbit ileal loop assays. Fluid accumulation in rabbit ileal loops was performed as
previously described (229). Briefly, 10 cm loops of small intestine were injected with 1 ml total
volume containing approximately 106 V. cholerae strain C6706 (El Tor) and various amounts of
CLA. A negative control loop was injected with 1 ml PBS. After 16 hours, the rabbits were
sacrificed and their intestines dissected out. Fluid volume from each loop was measured and CT
ELISA was performed to assess the mount of CT produced under each condition.
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RESULTS
CLA acts as a negative ToxT effector for activation of both TCP and CT. Our previous
work showed that linoleic acid decreased ToxT activity, leading to a decrease in virulence gene
expression (Chapter One). Here, we wanted to assess whether CLA would also exert negative
activity on ToxT, as measured by PtcpA expression as well as CT production. This would confirm
that CLA affects both major virulence factors in the classical biotype V. cholerae strain O395. To
begin, we used the highest concentration of CLA that did not affect bacterial growth, 128 µM.
In the presence of CLA, there is a significant reduction in P tcpA activity when V. cholerae is grown
under virulence-inducing conditions as compared to cultures grown in the same conditions, but
in the absence of CLA (Figure 15A). We then wanted to confirm that CLA had a similar effect on
the production of CT (Figure 15B). After growing the bacteria for three hours under virulenceinducing conditions, we looked at the supernatant to quantify the amount of secreted CT. CT
production was also significantly reduced in the presence of CLA. Thus these results indicate
that CLA works as expected to attenuate V. cholerae virulence gene expression in vitro
The CLA used in the previous experiment is a mixture of cis- and trans-9,11- and -10,12linoleic acid. To look at the different effects of each isoform, we used the lowest concentration
of the multi-isoform CLA that still had an effect on PtcpA expression, 32 µM. By using this
concentration, it allowed us to more easily compare effects of each isoform to one another as
more or less effective at decreasing PtcpA activity. To begin, we looked at CLA-ME. This is made
by the transesterification of CLA with methanol. This compound had no effect on promoter
expression even at a concentration 20 times the amount we used of the other CLA forms,
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indicating it is the fatty acid and not only its aliphatic chain that is involved in downregulation of
ToxT activity, and thus virulence gene expression (Figure 16). Next, we looked at the three
most common isoforms of CLA and their effects on promoter expression (9E,11E-, 9Z,11E-, or
10E,12Z-CLA). Although all three isoforms caused a significant decrease in virulence gene
expression, each did not do so to the same extent. Of the three isoforms, 9Z,11E-CLA was the
most effective at reducing expression and slightly more effective than the CLA mixture but this
was not statistically significant. 9E,11E-CLA affected promoter expression the least. Therefore,
the different isoforms of CLA do not all affect the PtcpA to the same extent.
ToxT binding activity is reduced in the presence of CLA. Previously we showed that
linoleic acid was able to directly affect ToxT-binding to DNA, by using EMSA (Chapter One).
Here, we used this same technique to determine if CLA also affected ToxT-binding to DNA. We
also used this information to get the ToxT binding curve and the equilibrium constant, Kd. We
again used the PtcpA as our DNA probe labeled with

32

P while adding increasing amounts of

purified MBP-ToxT to binding reactions. To each reaction we added DMSO to act as our solvent
control (Figure 17A, lanes 1-7) or 32 μM CLA dissolved in DMSO (Figure 17A, lanes 8-14) and
brought the binding reactions to equilibrium for 30 minutes. These reactions were then run on
a 6% polyacrylamide gel, followed by autoradiography and analysis using ImageJ software.
Densitometry analysis was used to calculate the percent bound MBP-ToxT of each
concentration and then put into GraphPad to get a binding curve as previously described
(Chapter one). The Kd with no CLA was 5.724nM and the Kd with CLA was 32.07nM. These
values are significantly different from each other (Figure 17B).
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Assessment of in vivo effects of CLA on virulence factor production. The results
described so far indicate that CLA has a strong negative effect on ToxT activity in vitro, as
assessed by both gene expression (CT production and P tcpA activity) and DNA binding (EMSA).
The next step was to determine whether administration of CLA in animal models for cholera
would reduce virulence factor production, leading to decreased colonization and/or fluid
accumulation induced by CT. The two most common animal models for cholera are the 3-5 day
old infant mouse model and the adult rabbit ileal loop model. The former is an excellent model
for assessing colonization, but does not produce a disease state in the mice. The latter is an
excellent model for assessing CT production, which is exhibited by fluid accumulation in the
ileal loops. Both models were used to determine whether CLA could reduce V. cholerae
colonization and/or CT production.
First, V. cholerae colonization was assessed using the infant mouse model. Because
infant mouse colonization requires TCP production, this would generally assess whether CLA
inhibits TCP production in vivo. Mice were infected with classical biotype V. cholerae strain
O395 or an isogenic toxT deletion strain as a negative control. Groups of mice infected with
wild-type O395 were either given PBS as a control or CLA at the time of infection, then boosted
with the appropriate reagent at 3 hours and 6 hours post-infection.
The results of these experiments are shown in Figure 18. CLA did not cause a significant
decrease in colonization levels in infant mice. However, there were numerous problems with
using this model. First, the inoculum was limited to 50 l, due to the size of the mouse pups.
CLA is also very viscous and difficult to pipet, which required that it be dissolved in a nonaqueous carrier that could then be emulsified in PBS for administration. This severely limited
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the amount of CLA that could be administered to the mouse pups. Therefore, although this is a
negative result, it may not be a good indicator of whether CLA would actually work in vivo in
the human gut.
Second, CT production was assessed using the rabbit ileal loop model. In this case, a
larger inoculum of 1 ml was used in each loop, which made administration of CLA much easier.
CLA was either dissolved in ethanol and then suspended in PBS or dissolved in sterile corn oil,
which is used in vaccine preparations. Preliminary results indicated that ethanol alone inhibited
CT production, probably due to its toxic effects on the bacteria, so this was excluded from later
experiments. El Tor strain C6707 was used in these experiments due to its stronger similarity to
currently circulating disease strains. Figure 19 show the results of a representative ileal loop
experiments. The administration of CLA, by separate injection, at the time of bacterial
inoculation resulted approximately three-fold lower fluid volumes that when wild-type C6706
was injected without CLA (Figure 19A). CT ELISA indicated that the CT levels were also reduced
when CLA was administered (Figure 19B). By combining the data from these two observations,
the overall outcome of these experiments was that the total amount of CT produced per loop
was approximately six-fold lower when CLA was administered (Figure 19C). While this was not
as strong of an effect as having toxT deleted (Figure 19A), it did strongly suggest that
administration of CLA in vivo could significantly reduce CT production, which could have an
effect on the duration and intensity of disease.
DISCUSSION
Because of our findings that linoleic acid has such a strong inhibitory effect of ToxT
activity, using the related compound conjugated linoleic acid (CLA) as a prophylactic or

82
therapeutic after exposure to V. cholerae became a possibility. There is a strong negative effect
of CLA on virulence gene expression as shown by both PtcpA activity and CT expression, as well
as a decrease in ToxT binding to its toxboxes sites on the PtcpA (EMSA). Different isoforms of CLA
showed some minor differences in effect but no major differences, making CLA production
easier as currently available mixtures could be used in over-the-counter therapies.
Although the infant mouse model showed no reduction in colonization, the model was
slightly flawed as potentially we could not add a high enough CLA concentration to reduce
virulence gene expression. This also only looked at O395 classical biotype, and it is possible that
with El Tor, the more common biotype in the environment, would give different results. The
duration of colonization could not be determined, and it is possible CLA could reduce its length.
These are preliminary data, and more troubleshooting could lead to better and more complete
results. Potentially even using a better solvent for CLA would help. The rabbit ileal loop model,
showed great promise, however, as CT production was greatly reduced, showing that although
CLA does not reduce colonization, it may reduce symptoms. Although these results are
preliminary, the use of CLA with V. cholerae shows promise in reduction of disease. Future
research will determine whether this will be a feasible and effective addition to current
rehydration therapy.
All in vitro experiments were performed by me, but the in vivo work was done by our
collaborators in India through NICED with Hemanta Koley, Ph.D.

b)

800
600
400
200
0

500

CT
ng/mL/OD600

a)

PtcpA::lacZ Expression
(Miller Units)

83

****
DMSO

128M CLA

Condition

400
300
200
100
0

***
DMSO

128M CLA

Condition

FIGURE 15. Cultures grown under inducing-conditions in the presence of CLA have
downregulated virulence gene expression. (A) Looking at tcpA::lacZ activation by ToxT by βgalactosidase assay showed significant downregulation of promoter activity upon the addition
of 128μM CLA. (B) CT expression was downregulated in the presence of CLA. Statistical
significance determined using Student’s t-test, *(p<.0001).
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FIGURE 18. Infant mouse colonization assays. Each symbol represents the data from one
mouse. CLA was administered using either Kolliphor RH-40 (Kr) or Kollidon 25 (Kn) as a carrier.
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CHAPTER FOUR
Identifying genes involved in the response to bile in Vibrio cholerae using fluorescenceactivated cell sorting
Abstract
Vibrio cholerae causes the severe diarrheal illness cholera. Previous studies have shown
that bile and its unsaturated fatty acid (UFA) components reduce virulence gene expression.
The mechanism for the bile-mediated reduction of toxin co-regulated pilus and cholera toxin
expression through the inhibition of ToxT activity has been described in earlier chapters of this
dissertation, but it is thought that there are also other genes involved in the direct response to
bile. To further characterize the mechanisms for bile inhibition of virulence gene expression,
we used transposon mutagenesis to make a V. cholerae mutant library containing gene
knockouts throughout the genome. Using fluorescence activated cell sorting methods, we
screened and sorted the mutants using a virulence gene promoter (tcpA) fused to the gene
encoding green fluorescent protein (gfp) to look for mutants that no longer caused a
downregulation of tcpA promoter expression in the presence of bile or UFA. This method has
resulted in identification of multiple mutants with insertions in pckA, which causes lowered
sensitivity to bile when mutated or deleted. PckA is known to be involved in the citric acid cycle
but potentially has another role in virulence. Identifying and characterizing the genes involved
in the response to bile/UFAs will give us a clearer understanding of the regulatory networks
controlling virulence gene expression.
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INTRODUCTION
V. cholerae is the causative agent of the severe diarrheal disease cholera. Cholera is
characterized by voluminous diarrhea. In order to initiate disease, production of two virulence
factors is necessary: cholera toxin (CT) and toxin co-regulated pilus (TCP) both dependent on
the major transcriptional protein activator ToxT. In the environment, V. cholerae expresses
motility genes which encode a single, polar flagellum that is used to penetrate the mucus layer
of the small intestine where V. cholerae then colonizes on the surface of epithelial cells (40).
Upon finding a site for colonization, the bacteria then downregulate motility gene expression
and upregulate virulence gene expression (40, 41). At the site for colonization, many host
chemicals are present, but two, bile and bicarbonate, have been identified as a negative and
positive effectors of ToxT, respectively (160, 202-205).
Bile is secreted by the gall bladder and is a heterogeneous mixture of many different
components including bile salts, saturated and unsaturated fatty acids, cholesterol, proteins,
and phospholipids. Bile normally acts as a fat emulsifier and bactericide, but V. cholerae uses it
as a chemical signal. When added in vitro, bile is shown to cause decreased production of TCP
and CT, and increased motility, biofilm formation, and outer membrane protein quantities (203205).
To identify genes important for the response to bile, we made a transposon mutant
library to look for mutants that were insensitive to the effect of bile. This was done by using the
promoter of tcpA fused to gfp, such that when virulence gene expression is induced by ToxT,
GFP is produced and can then be used as the marker for virulence gene induction. With GFP as
our marker, we used fluorescence activated cell sorting (FACS), which has been previously
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established as a method to isolate bacteria of interest from liquid cultures (230). Using this
technology we looked for mutants grown in liquid culture that no longer downregulated
virulence gene expression in response to bile and therefore were expressing high levels of GFP.
By using FACS, we were able to collect these mutants for further identification and
characterization. In doing so, we found several genes whose disruption was correlated with a
decrease in sensitivity to bile, but a gene involved in the citric acid cycle, pckA, was the most
common. Isolating mutants of V. cholerae that are no longer sensitive to bile allows us to
identify genes that are involved in the bile response and gives us greater insight into how
environmental signals affect virulence.
MATERIALS AND METHODS
V. cholerae strains and growth conditions. All V. cholerae strains used in the study are
from classical biotype O395 and this strain was also used to construct the transposon mutant
library. Strains and transposon mutants were maintained in Luria Broth (LB) containing 20%
glycerol and stored at -70°C. A PtcpA::gfp fusion used for flow cytometry was made on pTL61T
and PtcpA::lacZ used for β-galactosidase assays was inserted into the chromosome using pKAS32
and conjugation. Overnight cultures were grown overnight at 37°C in LB and then diluted 1:40
into LB pH 6.5 at 30°C for virulence inducing conditions in the presence or absence of freshly
prepared .05% bile (sodium choleate) or 160µM linoleic acid. V. cholerae strains were grown
with antibiotic concentrations: streptomycin at 100µg/mL, ampicillin at 100µg/mL, and
kanamycin at 50µg/mL. A deletion of the discovered bile insensitive mutant in pckA was made
as previously described in a PtcpA::lacZ chromosomal fusion in V. cholerae O395 classical to
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characterize (220). This strain containing pckA in pBAD33 was also made as a complement to
express in trans. Deletions of phosphoenolpyruvate carboxylase and isocitrate dehydrogenase
were also made and put into V. cholerae with a PtcpA::lacZ chromosomal fusion.
Transposon mutagenesis. Previously a transposon library had been made using the
suicide plasmid pFD1 in our lab (230). Here we followed the same procedure. Briefly, V.
cholerae was co-incubated with SM10 (λpir) in E. coli on nitrocellulose filter paper for three
hours at 37°C. Cells were added to media with streptomycin, ampicillin and 2 mM IPTG to
induce transposase expression. Bacteria were grown overnight and then transposon mutants
were selected on LB plates with streptomycin, ampicillin and kanamycin. Plates were incubated
for 7 hours at 37° C to allow for sufficient colony formation. Colonies were then collected and
cultured in LB under inducing conditions with 0.5% sodium choleate (bile) or 160 µM linoleic
acid. Bacteria alone were also cultured as a control. Collected mutants were directly sequenced
using genomic DNA and primers that bind near the ends of the transposon: BP30 (5′ATGCATTTAATACTAGCGACGCC-3′) or BP 31 (5′-CGCTCTTGAAGGGAACTATGTTG-3′).
Flow cytometry and FACS. As previously described (230), V. cholerae classical strain
O395 and an otherwise isogenic strain containing a PtcpA::gfp chromosomal fusion were grown
under virulence-inducing conditions for 3 hours in the presence or absence of bile or linoleic
acid. V. cholerae lacking the gfp fusion was grown in the absence of effector to set the
parameter channels of the flow cytometer and the cell sorter in the three parameters; forward
scatter (FSC), sideward scatter (SSC) and green fluorescence (515–545 nm), using a logarithmic
scale. For flow cytometry analysis, the expression of gfp was measured by using a FACSscan
flow cytometer (Becton Dickinson) and the data were further analyzed with FlowJo analysis
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software. For bacterial sorting, high GFP-expressing mutants were sorted using a FACS Diva
(Becton Dickinson) into LB media and plated to save individual colonies on LB plates with
ampicillin, streptomycin and kanamycin.
β-galactosidase assays and CT ELISA. β-galactosidase activity was measured using the
basic procedure of Miller to confirm mutants were insensitive to bile (212). CT was detected in
the culture supernatant by a GM1 enzyme-linked immunosorbent assay (ELISA) (228), using
polyclonal anti-CT antibody (Sigma). All strains and mutants tested were grown under virulenceinducing conditions for three hours with and without bile and compared.
RESULTS AND DISCUSSION
PtcpA::gfp shows decreased expression in the presence of bile or linoleic acid. To look at
the effect of bile on virulence gene expression, we used a previously constructed gfp plasmid
fusion that contains the promoter of tcpA. TCP is one of the major virulence factors necessary
for host colonization and therefore is a useful indicator of virulence gene expression. As an
experiment for proof-of-concept, we began by looking at the effect of bile or one of its
unsaturated fatty acid components, linoleic acid, on P tcpA expression using flow cytometry
(Figures 20A,B). After growing the bacteria under virulence-inducing conditions either alone or
in the presence of one of the effectors, we measured GFP expression. Without bile or linoleic
acid, there were high levels of GFP expressed, but upon the addition of either of the negative
effectors, GFP levels were low. Figure 20B also shows that, at a concentration as low as 16 µM,
linoleic acid still has an effect on tcpA, but at a concentration lower than that, virulence
expression is unaffected. These data indicate that GFP levels are high under virulence-inducing
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conditions, and low upon the addition of negative effectors, indicating this will be a useful
screening system for use with FACS collection and analysis.
Collection of V. cholerae mutants potentially insensitive to bile by FACS. The general
strategy to collect bile insensitive mutants is shown in Figure 21A. We began by creating a
mariner-based transposon mutant library in V. cholerae O395 that carried chromosomal
PtcpA::gfp. To identify mutants that had lower sensitivity to bile, and therefore had high GFP
expression in the presence of bile (Figure 21C), we grew the mutant pool in the presence of bile
and selected for the highest expressing GFP producers (Figure 21D). We then took this pool,
grew the bacteria overnight in LB alone to allow recovery, and then subjected the pooled
mutants to bile treatment again under virulence-inducing conditions, hoping to enrich for the
mutants that were the least sensitive to effects of bile and thus had the highest GFP levels
(Figure 21E). On the second day of sorting, there were more mutants expressing high levels of
GFP, and these mutants were collected for further characterization.
pckA was identified as the most common mutant in the screen. After FACS analysis,
mutants were characterized by β-galactosidase assay to ensure that the transposon insertion
was not present in the PtcpA::gfp construct to somehow cause constitutive activation of GFP.
Each mutant was tested individually to look at bile sensitivity. The most common disrupted
gene found in the screen was pckA, encoding phosphoenolpyruvate carboxykinase, an enzyme
involved in central metabolism that converts oxaloacetate into phosphoenolpyruvate. Another
gene involved in cell envelope biosynthesis was identified as well, D-alanyl-D-alanine
carboxypeptidase, but was not studied further.
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Although the high number of individual pckA mutations recovered from the screen was
initially promising and suggested a key role for pckA in virulence, ΔpckA strains quickly reverted
back to wild-type levels of virulence activity, making it very difficult to characterize them
further. Compared to wild-type, ΔpckA showed only a slight decrease in bile sensitivity in both
β-galactosidase assays and cholera toxin ELISAs (Figures 22A,B,C). In fact, in the absence of bile,
ΔpckA actually made more cholera toxin when grown under inducing conditions. It is certainly
possible, if not probable, that the ΔpckA strain acquired a secondary mutation that
compensated for the deletion and increased bacterial fitness, as we suspect was rapidly
happening with the pckA transposon insertion mutants. In spite of this, we examined other
genes involved in the citric acid cycle to determine whether central metabolism may play a role
in virulence gene expression levels (Figure 22C). Phosphoenolpyruvate carboxylase, which
converts phosphoenolpyruvate into oxaloacetate, is an enzyme that works in the opposite
direction of PckA, and, when deleted, showed no difference in virulence gene expression
compared to wild-type (Figures 22D,E). Isocitrate dehydrogenase, which works at the ratelimiting step of the citric acid cycle to convert isocitrate into α-ketoglutarate, also showed no
effect on virulence expression when deleted (Figures 22D,E). That said, more recent evidence
suggests that metabolic proteins may have multiple functions and therefore act as
“moonlighting proteins” (231). These proteins are generally highly conserved (232, 233).
Although pckA has not yet been discovered to have multiple roles aside from metabolism, the
possibility is there. The fact that the ΔpckA strain very quickly reverted back to wild-type
virulence gene expression levels demonstrates the importance of this gene to bacterial fitness.
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Even though the insensitivity of bile was a modest effect, at only a 10% difference from wildtype (Figure 3B), the possibility is there that pckA may have a small role in virulence regulation.
FACS is a useful technique that could be used in other liquid-based screens to identify
genes involved in other types of effectors or conditions. As only the highest expressing GFP
mutants were collected, it may be more useful in future work to collect other mutants that
were expressing GFP levels more comparable to bacteria grown without bile.
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a)

b)

FIGURE 20. Flow cytometry of negative effectors on virulence expression. Classical biotype
O395 V. cholerae was grown under virulence-inducing conditions. All histograms show the level
of gfp fluorescence intensity with a tcpA::gfp fusion plasmid. Cells alone have no gfp reporter
plasmid and are used to gate proper cell size and as a negative control (A) V. cholerae grown
with or without the presence of .05% bile. (B) V. cholerae (B) V. cholerae grown with various
dilutions of linoleic acid.
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a)

FIGURE 21. Collecting bile insensitive mutants using FACS (A) A general strategy for developing
a transposon mutant library for identifying genes involved in response to bile. (B)-(D) FACS
analysis of V. cholerae (B)V. cholerae grown without gfp as a size control (C) V. cholerae grown under
virulence-inducing conditions without bile with high expression of PtcpA::gfp. (D) A range
of gfp expressing mutants was produced when grown under inducing conditions. Most of the mutants
produce low fluorescence while some produced high gfp. (E) After overnight enrichment of high gfp
expressing mutants, most mutants express high levels of gfp
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FIGURE 22. Characterization of pckA involvement in virulence regulation. (A) V. cholerae was
grown under virulence-inducing conditions. β-galactosidase assay with and without .05% bile.
WT – wild-type, pckAΔpckA is deletion strain with a pckA complement in pBAD33 (B) Data
expressed as a percent of activity between bile compared to no bile for WT and ΔpckA (C) CT
expression with and without .05% bile from the supernatant of V. cholerae grown under
virulence-inducing conditions (D) Citric acid cycle and location of deleted genes (E) Other
metabolism genes deleted and grown under virulence-inducing conditions with and without
.05% bile. PEPCase – phosphoenolpyruvate carboxylase, IDH – isocitrate dehydrogenase.
Statistical significance determined using Student’s t-test (*, p<.05; **, p<.005; ***,p<.0005).
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CONCLUSIONS
Vibrio cholerae virulence gene expression is controlled by a complex regulatory cascade
with its master gene regulator ToxT. ToxT directly activates the promoters of the two major
virulence factors, cholera toxin (CT) and toxin-coregulated pilus (TCP). When V. cholerae
colonizes the small intestine, it is able to use environmental signals produced by the host to
regulate its gene expression. These environmental effectors include the positive effector,
bicarbonate, as well as the negative effector bile, partially composed of unsaturated fatty acids
(UFAs) that are thought to be directly responsible. This study has been aimed at elucidating the
mechanism by which bile and its unsaturated fatty acid components act to downregulate
virulence.
Here, we show that bile and UFAs decrease virulence gene expression. Linoleic acid,
specifically, is able to enter the cell, where it can then act on ToxT in the cytoplasm. These
negative effectors act directly on ToxT, causing decreased binding affinity of ToxT for the
promoters of virulence genes including acfA, acfD, aldA, tagA, tcpA, and tcpI. As most
promoters have two ToxT binding sites, it has been hypothesized that ToxT acts as a dimer and
UFAs decrease the ability of ToxT to dimerize. However, aldA only has one ToxT binding site,
and the observations that aldA gene expression was downregulated and the ability of ToxT to
bind to the aldA promoter was inhibited by linoleic acid suggest a mechanism by which UFAs
affect monomeric ToxT. As the data showed, aldA activity was substantially lower than the two
ToxT-binding site promoters, suggesting that ToxT dimers activate better, but ToxT monomers
can still activate gene expression. Interestingly, in RNAseq experiments, aldA was the gene
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whose expression was most highly upregulated in the presence of bicarbonate, the positive
ToxT effector (data not shown).
The unstructured region of ToxT, found when ToxT was crystalized, was mutated to look
at the effect of bile and UFAs on ToxT itself. We found mutations that were involved in
response to bile and UFAs. The activity of one mutant in particular, N106F, was not affected by
the addition of bile or UFAs in terms of virulence gene expression as well as ToxT EMSAs. We
hypothesize that the large phenylalanine residue may mimic the conformation of ToxT when
bicarbonate is bound, and therefore, bile and UFAs no longer have an effect.
Conjugated linoleic acid (CLA) was studied for a potential use as a prophylactic or
therapeutic. In vitro CLA downregulates virulence gene expression substantially. Using the
infant mouse model, CLA had no effect on V. cholerae colonization. However, there were
significant problems with using this particular animal model for these experiments. Rabbit ileal
loop assays indicated that both fluid volume and CT concentration were lowered in the
presence of CLA, suggesting that CLA may be effective as a therapeutic to reduce disease
symptoms. Further work will be necessary to explore this possibility.
Last, a transposon mutant library for use in fluorescence activated cell sorting (FACS)
genetic screening identified an insertion in pckA, a gene important in metabolism. The pckA
mutant showed higher expression levels of PtcpA-gfp in the presence of bile. Further studies
showed that a pckA deletion mutant was only slightly less sensitive to bile, but this does
suggest that genes important in metabolism can have effects on virulence gene expression.
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Future Directions
Although much work has been done to determine the mechanism by which UFAs
downregulate virulence, there is still much work that can be done. To begin, it would be useful
to use the two-hybrid bacterial system to look at linoleic acid’s effect on dimerization. Although
our data suggest it is not dimerization by which linoleic acid decreases ToxT DNA binding
affinity, this would add further confirmation. Although not discussed in this dissertation,
surface plasmon resonance (SPR) was explored to identify binding changes upon addition of
linoleic acid. Further exploration of this technique could give real-time data of the binding
patterns of ToxT in response to linoleic acid, and potentially, the heterogeneous mixture of bile.
This could include using the ToxT mutations in the unstructured region and comparing binding
patterns as well. Also, the interplay of linoleic acid and the positive effector bicarbonate is
something that could be further explored either through more EMSAs or SPR. Adding an
additional toxbox to the aldA promoter or removing one from a promoter with two toxboxes
may give some more useful information on the regulation of the effectors. Also, we could use
human epithelial cells and add exogenous bile and/or bicarbonate to study surface colonization
that could give greater understanding to how these effectors may act in the host.
The CLA aspect of this project shows a substantial negative effect of CLA in vitro.
Experiments with rabbit ileal loops also indicated that CLA reduced CT production in vivo. The
use of CLA as a prophylactic or therapeutic could be useful, but much work still needs to be
done including identifying the right concentrations of CLA to use.
Characterization of the other genes identified in the FACS screen would also be useful.
Potentially there is a transport mechanism that imports UFAs into the cell, and discovery of
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genes responsible for this would further our knowledge of a location in which other negative
effectors (therapeutics) could target to reduce disease in humans.
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Vibrio cholerae is responsible for the diarrheal disease cholera by producing two major
virulence factors: cholera toxin (CT) and toxin-coregulated pilus (TCP). During infection, V.
cholerae downregulates its motility genes, which are actively expressed in the environment,
and upregulates its virulence genes, which are inactive in the environment. Virulence gene
transcription is regulated by the major transcriptional activator, ToxT. ToxT is regulated, in part,
by host signals, which in turn, make ToxT active or inactive in respect to virulence gene
expression. Host signals include temperature and pH as well as the chemical molecules
bicarbonate and bile, which are positive and negative effectors of virulence, respectively. Bile is
a heterogeneous mixture that includes unsaturated fatty acids (UFAs) that have been directly
implicated in virulence gene downregulation. Another small molecule, virstatin, has also been
shown to cause virulence gene downregulation. This dissertation focuses on the mechanism by
which bile and its UFA components, specifically linoleic acid, downregulate virulence gene
expression.
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The first chapter focuses on the decreased binding affinity of ToxT for various virulence
gene promoters at the ToxT binding sites, termed toxboxes. These toxboxes come in different
configurations and orientations, and while most promoters have two toxboxes, aldA only has
one. I showed that linoleic acid can enter the cell where it can go into the cytoplasm and then
interact with ToxT. It has been hypothesized that UFAs cause decreased dimerization; however
at PaldA, linoleic acid still had an effect. Virstatin, which has been shown directly to decrease
dimerization of ToxT, did not have an effect on ToxT DNA binding at PaldA. This suggests a
mechanism in which UFAs do not affect dimerization but can affect monomeric ToxT binding to
DNA.
In chapter two, we characterize an unstructured region of the N-terminal domain of
ToxT in response to bile and UFAs. By mutating each of the 10 amino acids in the region, we
discovered a mutant, N106F, which had decreased response to bile and UFAs. It also showed
decreased response to the positive regulator bicarbonate.
Chapter three discusses the possibility of using conjugated linoleic acid (CLA) as a
therapeutic or prophylactic upon exposure to V. cholerae. The in vitro work showed a strong
decrease of ToxT activity in response to CLA on both gene expression and DNA binding. In the
infant mouse model, CLA did not inhibit colonization, but in the rabbit ileal loop model CT
production was significantly decreased, suggesting that CLA may work to reduce cholera
symptoms.
In the last chapter, we looked at the possibility of using fluorescence-activated cell
screening (FACS) in addition to transposon mutagenesis as a method to collect mutants that
were insensitive to bile. Use of this technique would allow us to discover genes that were
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directly responsible for the effects of bile. Several genes were identified, including pckA, which
is involved in metabolism, but could have a role in virulence. When deleted, however, the
bacteria were only slightly less sensitive to bile than wild-type. FACS genetic screening is still a
useful technique that, if further explored, could elucidate other genes involved in responding to
effectors of virulence.
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